CA2376159C - Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method - Google Patents
Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method Download PDFInfo
- Publication number
- CA2376159C CA2376159C CA2376159A CA2376159A CA2376159C CA 2376159 C CA2376159 C CA 2376159C CA 2376159 A CA2376159 A CA 2376159A CA 2376159 A CA2376159 A CA 2376159A CA 2376159 C CA2376159 C CA 2376159C
- Authority
- CA
- Canada
- Prior art keywords
- drug
- derivative
- acid
- plasma protein
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
Abstract
A method of the administration of drugs with binding affinity for plasma protein and drugs regulating the effective ingredient dose of drugs with binding affinity for plasma protein; and a preparation whereby the effective ingredient dose of drugs with binding affinity for plasma protein is regulated. The above administration method is characterized in that, in the administration of a first drug having binding affinity for plasma protein, a second drug having binding affinity for the same plasma protein is administered simultaneously with the first drug or before or after the administration of the first drug to thereby regulate the binding of the first drug to the plasma protein.
Description
DESCRIPTION
METHOD OF THE ADMINISTRATION OF DRUGS HAVING
BINDING AFFINITY WITH PLASMA PROTEIN AND
PREPARATION TO BE USED IN THE METHOD
TECHNICAL FIELD
The present invention relates to a method of the administration of drugs with binding affinity for plasma protein and drugs regulating the effective ingredient dose of drugs with binding affinity for plasma protein; and a pharmaceutical preparation whereby the effective ingredient dose of drugs with binding affinity for plasma protein is regulated.
BACKGROUND ART
Generally, drugs administered for the purpose of medical treatment or diagnosis once go through the systemic blood circulation, and then take the process of absorption, distribution, metabolism, excretion and the like. In the process of absorption and distribution, the drug moves along on flow of the blood, while it transfers to each spaces of intravascular, interstice and intracellular by diffusion and transportation of a free drug being in the state of unbound form with proteins, and finally the drug arrives at the active region of target.. When movement of the drug reaches a steady state, then the free drug concentration in each space become uniform, thus the whole pattern of the concentration of the drug is determined by the binding level with proteins. Hence, in accordance with the property, a drug in vivo, may partially exists in the form of reversible binding state with biopolymers such as plasma proteins. Generally, drugs permeable through capillary wall or cell membrane are free drugs, therefore, the transfer of such free drugs being unbound with plasma proteins to the active region of target may be greatly influenced by the binding level with plasma proteins.
For example, mercaptoacetylglycylglycylglycine labeled with 99m-technetium (99mTc-MAG3) is widely used in renal scintigraphy, especially the renal plasma flow can be effectively exhibited by its efficient renal extraction and renal tubular secretion. It is known that about 90% of 99mTc-MAG3 binds to plasma protein in an ordinary clinical dose (Bubeck B. et al., J. Nucl.
Med., -U, 1285-1295, 1990). If the binding of 99mTc-MAG3 with plasma protein is inhibited by drugs having high binding affinity to the same binding site on protein with 99mTc-MAG3, then more clear renal imaging can be obtained in the earlier stage after the administration, thus it may be thought that the dose of radioactivity to the patient can be reduced at the same time.
On the contrary, if the binding of drugs with plasma protein is increased, then the concentration of the free drugs in the blood can be kept in lower level for long period, therefore, it may be possible to achieve continuous appearance of pharmacological effects.
However, at the present stage, little is known as the research work for improving therapeutic effect or diagnostic effect of the drugs by regulating the concentrations of the free drugs, using the binding affinity of the second drug with plasma proteins.
DISCLOSURE OF THE INVENTION
In consideration of the above-mentioned problems, an object of the present invention is to provide a suitable method of the administration of drugs by regulating the binding affinity of the drug for plasma proteins, and at the same time, to provide a pharmaceutical preparation whereby the binding affinity of the drug for plasma protein can be regulated.
According to the present invention, the suitable administration of the drugs can be achieved by regulating the binding affinity of the drug for plasma protein, and at the same time, a pharmaceutical preparation for such administration can be provided.
The present invention relates to a method of administration of drugs with binding affinity for plasma protein, characterized by regulating the binding affinity of the first drug for plasma protein, when administering the first drug with the binding affinity for plasma protein, the second drugs, which have the binding affinity for the same plasma protein, for which the first drug has binding affinity, is administered simultaneously with the first drug or before or after the administration of the first drug.
Particularly, in the case of regulating the binding affinity of the first drug for plasma protein, it is preferable that the first drug and the second drugs bind to the same binding sites on the plasma protein. Further, the second drug may be administered before, after or simultaneously with the administration of the first drug, and such administration timing of the second drug can be suitably selected in connection with the timing when the free drug concentration of the first drug reaches to the level so as to obtain an adequate effect. Additionally, a single drug may be used as the second drug, or plural drugs may be used as the second drugs when synergistic effect can be expected.
In case of administering the first drug and the second drug simultaneously, the pharmaceutical preparations comprising the first drug and the second drug may be supplied. Further, the first drug and the second drug may be filled in a container separately, and may be supplied as a kit form. In case of such a kit form with separate containers, they may be administered simultaneously by mixing it together when used, or each one of the first drug and the second drug can be administered in different times separately or by different route. Furthermore, both of or either one of these first and second drugs may be commercially available pharmaceuticals.
When the first drug is radiodiagnosic agent for j vivo use or radiotherapeutic drug for im vivo use, the radioactive nuclides can be selected from the 5 group comprising 11-carbon (11C), 15-oxygen (150), 18-fluorine, (18F) , 32-phosphorus (32P) , 59-iron (57Fe) , 67-copper (67Cu) , 67-gallium (67Ga) , 81m-krypton ("'Kr) , 81-rubidium (81Rb) , 89-strontium (B9Sr) , 90-yttrium (90Y) , 99m-technetium (95m'Tc) , 111-indium (111In) , 123-iodine (123I) , 125-iodine (125I) , 131-iodine (131I) , 133-xenon (133Xe) , 117m-tin (117 iSn) , 153-samarium (153Sm) , 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (2O1T1) , 212-bismuth (212Bi) , 213-bismuth (213Bi) and 211-astatine (211At) .
In this case, compounds, such as chelating group or receptor ligand, of the first drug labeled with the above-mentioned nuclides can be selected from bisaminothiol or its derivatives, monoaminomonoamidobisthiol or its derivatives, bisamido-bisthiol or its derivatives, mercaptoacetylglycylglycyl-glycine or its derivatives, hexamethylpropylene-amineoxime or its derivatives, ethylenebis[bis(2-ethoxyethyl)phosphine](tetrofosmin) or its derivatives, 2,3-dimercaptosuccinic acid or its derivatives, ethylenecysteine dimer derivatives, methoxyisobutylisonitrile derivatives, polyamine derivatives, pyridoxylydeneaminate derivatives, methylene diphosphonate, hydroxymethylene diphodphonate 1 j derivatives, 13-methyl-co-phenylpentadecanoic acid or its derivatives, N-isopropyl-amphetamine, hippuric acid, benzylguanidine, tropane derivatives and the like.
The second drug may be selected from, for example, bucolome, cefazolin, etoposide, phenylbutazone, aspirine, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-2-naphtyl acetic acid, ibuprofen, probenecid, dan.syl-L-asparagine -(DNSA), verapamil or disopyramide and the like.
According to one aspect of the invention there is provided use, in the manufacture of a medicament, of:
a first drug having a binding affinity for a plasma protein;
wherein the first drug is a radiotherapeutic drug having a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150) , 18-fluorine, ('8F) , 32-phosphorus (32P) , 59-iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga) , 81:m-krypton (81mKr) , 81-rubidium (81Rb) 89-strontium (89Sr) , 90-yttrium (90Y) , 99m-technetium (99mTc), 111-indium ("'In), 123-iodine (1211) , 125-iodine (12.51) , 131-iodine (1311) , 133-xenon (133Xe) , 117m-tin (11'mSn) , 153-samarium (153Sm) , 186-rhenium (186Re) , 188-rhenium (188Re) , 201-thallium (201T1) , 212-bismuth (212Bi) , 213-bismuth (213Bi) or 211-astatine (211At) ; and wherein the binding group of the first drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a 6a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a P-methyl-w-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and a second drug having a binding affinity for the plasma protein;
wherein the second drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the second drug binds to the plasma protein, thereby decreasing the binding of the first drug to the plasma protein.
According to a further aspect of the invention there is provided use, in the manufacture of a medicament, of:
a first drug having a binding affinity for a plasma protein;
wherein the first drug is a radiotherapeutic drug having a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150) , 18-fluorine, (18F) , 32-I I I
Erb phosphorus (32P) , 59--iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga), 81m-krypton (elmKr), 81-rubidium (81Rb) , 89-strontium (89Sr) , 90-yttrium (90Y) , 99m-technetium (99' Tc) , 111-indium (111In) , 123-iodine (1231) , 125-iodine (125I) 131-iodine (1311) , 133-xenon (133Xe) , 117m-tin (117mSn) , 153-samarium (153Sm) , 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201T1) , 212-bismuth (212Bi) , 213-bismuth (213Bi) or 211-astatine (2"At) ; and wherein the binding group of the first drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a (3-methyl-6)-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and a second drug having a binding affinity for the plasma protein;
wherein the second drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the second drug binds to the plasma protein, thereby increasing the binding of the first drug to the plasma protein.
According to another aspect of the invention there is provided use, in the manufacture of a medicament, of:
a drug having a binding affinity for the plasma protein;
wherein the drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
wherein the drug is formulated for administration either before or after a radiotherapeutic drug having a binding affinity for a plasma protein;
wherein the radiotherapeutic drug has a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150), 18-fluorine, (18F) , 32-phosphorus (32P) , 59-iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga) , 81m-krypton (81mKr), 81-rubidium (81Rb) 89-strontium (89Sr) , 90-yttrium (90Y) , 99m-technetium (99mTC) , 111-indium (111In) , 123-iodine (1231) , 125-iodine (1252) , 131-iodine (1311) , 133-xenon (133Xe) , 117m-tin (117mSn) , 153-samarium (153Sm) , 186-rhenium (186Re) , 188-rhenium (188Re) , 201-thallium (201T1) , 212-bismuth (212Bi) , 213-bismuth (213Bi) or 211-astatine (211At) ; and wherein the binding group of the radiotherapeutic drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a 6d mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a R-methyl-w-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and whereby the drug binds to the plasma protein, thereby decreasing the binding of the radiotherapeutic drug to the plasma protein.
According to yet another aspect of the invention there is provided use, in the manufacture of a medicament, of:
a drug having a binding affinity for the plasma protein;
wherein the drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
wherein the drug is formulated for administration either before or after a radiotherapeutic drug having a binding affinity for a plasma protein;
wherein the radiotherapeutic drug has a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150) , :L8-fluorine, (18F) , 32-6e phosphorus (32P) , 59--iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga) , 81m-krypton (81mKr), 81-rubidium (81Rb) , 89-strontium (89Sr) , 90-yttrium (90Y) , 99m-technetium (99mTc) , 111-indium (111In) , 123-iodine (123I) , 125-iodine (125I) , 131-iodine (131I) , 133-xenon (133Xe) , 117m-tin (117mSn) , 153-samarium (153Sm) , 186-rhenium (186Re) , 188-rhenium (188Re) , 201-thallium (201T1) , 212-bismuth (212131) , 213-bismuth (213Bi) or 211-astatine (211At) ; and wherein the binding group of the radiotherapeutic drug is a bisaminothiol, a monoaminomonoamidobisth.iol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin), a 2,3-dimercaptosuccinic acid., an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a (i-methyl-ca-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and whereby the drug binds to the plasma protein, thereby increasing the binding of the radiotherapeutic drug to the plasma protein.
According to still another aspect of the invention there is provided a pharmaceutical composition for decreasing the binding of a first drug to plasma protein, which comprises:
1'o f a first drug having a binding affinity for plasma protein;
wherein the first drug is a radiotherapeutic drug having a binding group being labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150) , 18-fluorine, (18F) , 32-phosphorus (32P) , 59-iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga) , 81m-krypton (81mKr), 81-rubidium (81Rb) , 89-strontium (89Sr) , 90-yttrium (90Y) , 99m-technetium (99mTC), 111-indium ("1In), 123-iodine (1231) , 125-iodine (1211) , 131-iodine (131I) , 133-xenon (133Xe) , 117m-tin (117mSn) , 153-samarium (153Sm) , 186-rhenium (186Re) , 188-rhenium (188Re ) 201-thallium (201T1) , 212-bismuth (212Bi) , 213-bismuth (213Bi) or 21.1-astatine (211At) ; and wherein the binding group of the first drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropylenea.mineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a 1i-methyl-w-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and 6g at least one second drug having a binding affinity for the plasma protein;
wherein the at least second drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the at least one second drug binds to the plasma protein, thereby decreasing the binding of the first drug to the plasma protein.
According to a further aspect of the invention there is provided a pharmaceutical composition for increasing the binding of a first drug to the plasma protein, which comprises:
a first drug having a binding affinity for plasma protein;
wherein the first drug is a radiotherapeutic drug having a binding group being labeled with a radioactive nuclide:
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150) , 18-fluorine, ('8F) , 32-phosphorus (32P) , 59=-iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga), 81m-krypton (81mKr), 81-rubidium (81Rb) , 89-strontium (89Sr) , 90-yttrium (90Y), 99m-technetium (99mTc) , 111-indium (111In) , 123-iodine (1231) , 125-iodine (1251) , 131-iodine (131I) , 133-xenon (133Xe) , 117m-tin (117mSn), 153-samarium (153Sm) , 186-rhenium (186Re) , 188-rhenium (188Re), 201-thallium (201T1) , 212-bismuth (212Bi) , 213-bismuth (213Bi) or 211-astatine (211At) ; and 6h wherein the binding group of the first drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-et:hoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dieter derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a R-methyl-w-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and at least one second drug having a binding affinity for the plasma protein;
wherein the at least second drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the at least one second drug binds to the plasma protein, thereby increasing the binding of the first drug to the plasma protein.
According to another aspect of the invention there is provided a kit for non-medical diagnostic imaging, the kit comprising:
a first container containing a first substance having a binding affinity for plasma protein;
wherein the first substance is a radiodiagnostic substance having a binding group labeled with a radioactive nuclide:
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (15C)) , 18-fluorine, (18F) , 32-phosphorus (32P) , 59-iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga) , 81m-krvpton (81mKr) , 81-rubidium (81Rb), 89-strontium (89Sr) , 90-yttrium (90Y) , 99m-technetium (99mTc) , 111-indium ("1In) , 123-iodine (1231) , 125-iodine (1.251) , 131-iodine (1311) , 133-xenon (133Xe) , 117m-tin (117mSn) , 153-samarium (153Sm) , 186-rhenium (186Re) , 188-rhenium (188Re) , 201-thallium (201T1) ,. 212-bismuth (212Bi) , 213-bismuth (213Bi) or 211-astatine (211At) ; and wherein the binding group of the first substance is a bisarninothiol, a monoaminomonoamidob:Lsthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dieter derivative, a methoxyisobutylison_Ltrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a [3-methyl-ca-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and Eli a second container containing a second substance having a binding affinity for the plasma protein;
wherein the second substance is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
together with written instructions for their use for non-medical diagnostic imaging;
whereby the second substance binds to the plasma protein, thereby decreasing or increasing the binding of the first substance to the plasma protein.
According to yet another aspect of the invention there is provided use, in the manufacture of a diagnostic composition, of:
a first substance having a binding affinity for a plasma protein;
wherein the first substance is a radiodiagnostic having a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150) , 18-fluorine, (18F) , 32-phosphorus (32P) , 59--iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga) , 8:1m-krypton (81mKr) , 81-rubidium (81Rb) 89-strontium (89Sr) , 90-yttrium (90Y) , 99m-technetium (99mTc) , 111-indium (111In) , 123-iodine (1231) , 125-iodine (1251) , 131-iodine (1311) , 133-xenon (133Xe) , 117m-tin (117mSn) , 153-samarium (153Sm) , 186-rhenium (186Re) , 188-rhenium. (188Re) , Ei k 201-thallium (201T1) , 212-bismuth (212Bi) , 213-bismuth (213Bi) or 21_1-astatine (211At) ; and wherein the binding group of the first substance is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a (3-methyl-W-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and a second substance having a binding affinity for the plasma protein;
wherein the second substance is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the second substance binds to the plasma protein, thereby decreasing the binding of the first substance to the plasma protein.
According to still another aspect of the invention there is provided use, in the manufacture of a diagnostic composition, of:
6l a first substance having a binding affinity for a plasma protein;
wherein the first substance is a radiodiagnostic drug having a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150) , 18-fluorine, (18F) , 32-phosphorus (32P) , 59-iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga) , 81m-krypton (81mKr) , 81-rubidium (81Rb) , 89-strontium ("Sr) , 90-yttrium (90Y) , 99m-technetium (99mTc) , 111--indium (111In) , 123-iodine (123I) , 125-iodine (1251) , , 131-iodine (1311) , 133-xenon (133Xe) , 117m-tin (117mSn) , 153-samarium (153Sm) , 186-rhenium (186Re) , 188-rhenium (188Re) , 201-thallium (201T1) , 212-bismuth (212Bi) , 213-bismuth (213Bi) or 211-astatine (211At) ; and wherein the binding group of the first substance is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative,, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a 13-methyl-w-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and I 1 I i . I I
6m a second substance having a binding affinity for the plasma protein;
wherein the second substance is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the second substance binds to the plasma protein, thereby increasing the binding of the first substance to the plasma protein.
According to a further aspect of the invention there is provided use, in the manufacture of a diagnostic agent, of:
a substance having a binding affinity for the plasma protein;
wherein the substance is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
wherein the substance is formulated for administration either before or after a radiodiagnostic substance with binding affinity for a plasma protein;
wherein the radiodiagnostic substance has a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150) , 18-fluorine, (18F) , 32-phosphorus (32P) , 59=-iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga) , 8:1m-krypton (81mKr), 81-rubidium 6n (81Rb) 89-strontium (89Sr) , 90-yttrium (90Y) , 99m-technetium (99mTC) , 111-indium (1111n) , 123-iodine (1231) , 125-iodine (125I) , 131-iodine (1311) , 133-xenon (133Xe) , 117m-tin (117mSn) , 153-samarium (153Sm) , 186-rhenium (186Re) , 188-rhenium (188Re), 201-thallium (201Tl) , 212-bismuth (212Bi) , 213-bismuth (213Bi) or 21.1-astatine (21 'At); and wherein the binding group of the radiodiagnostic substance is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a (3-methyl-(z-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and whereby the substance binds to the plasma protein, thereby decreasing the binding of the radiodiagnostic substance to the plasma protein.
According to a further aspect of the invention there is provided use, in the manufacture of a diagnostic agent, of:
a substance having a binding affinity for the plasma protein;
6o wherein the substance is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
wherein the substance is formulated for administration either before or after a radiodiagnostic substance with binding affinity for a plasma protein;
wherein the radiodiagnostic substance has a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150) , 18-fluorine, (18F) , 32-phosphorus (32P) , 59-iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga), 81m-:krypton (81mKr), 81-rubidium (81Rb) , 89-strontium (89Sr) , 90-yttrium (90Y) , 99m-technetium (99mTc) , 111--indium (111In) , 123-iodine (1231) , 125-iodine (125I) , 131-iodine (131I) , 133-xenon (133Xe) , 117m-tin (117mSn) , 153-samarium (153Sm) , 186-rhenium (186Re) , 188-rhenium (188Re) , 201-thallium (201T1) , 212-bismuth (212Bi) , 213-bismuth (213Bi) or 211-astatine (21 'At); and wherein the binding croup of the radiodiagnostic substance is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative,, a pyridoxylydene aminate derivative, a methylene diphosphonate, a 6p hydroxymethylene diphosphonate derivative, a (3-methyl-w-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof;and whereby the substance binds to the plasma protein, thereby increasing the binding of the radiodiagnostic substance to the plasma protein.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 shows the free fraction of 99mTc-MAG3 in human plasma in the presence of site specific agent.
Fig. 2 shows the free fraction of 99mTc-MAG3 in rat plasma in the presence of site specific agent.
Fig. 3 shows the effect of bucolome on blood clearance of 99mTc-MAG3 in rat.
Fig. 4 shows the effect of bucolome on the free fraction of 95mTc-MAG3 in rat blood after administration of bucolome.
Fig. 5 shows the effect of bucolome on the accumulation of 95mTc-MAG3 in rat kidney after administration of bucolome.
Fig. 6 shows the effect of bucolome loading on the biodistribution of 99mTc-MAG3 in rat. mm 1c-MAG3 in rat.
Fig. 7 shows the renogram of 99mm BEST MODE FOR CARRYING OUT OF THE INVENTION
When the second drug having high binding affinity for the same plasma protein, for which the first drug has binding affinity, is administered simultaneously with the first drug, or before or after the administration of the first drug, then competitive displacement will take place at the binding site, thus it can be thought that the first drug may be released in a higher concentration (displacement effect).
Therefore, it can be expected that the higher pharmacological activity of the first drug can be obtained as compared with the case that the first drug is administered singly. On the contrary, when the binding fraction of the first drug to plasma protein increases by the effect of the second drug (reducing effect of the free drug concentration), continuous appearance of pharmacological effect of the first drug can be expected to achieve by keeping the free fraction of the first drug in blood at a lower level for long period.
In the present invention, the first drug with binding affinity for plasma protein may be either one of therapeutic agent or diagnostic agent, as long as it meets the purpose of administration.
Regardless of therapeutic or diagnostic purpose, in case of obtaining the above-mentioned displacement effect, the second drug may be preferably selected from those having competitive binding affinity for the same plasma protein as the first drug has;
increasing the free fraction of the first drug by the binding inhibition of the first drug with plasma protein; having the affinity for the same binding site of the first drug on plasma protein; and having the higher binding affinity for plasma protein.
On the contrary, in case of obtaining the above-mentioned reducing effect of the free drug concentration, the object is achieved by selecting the second drug from those having effect to increase the binding affinity of the first drug for plasma protein by the second drug bound to the same plasma proteins.
At the present, a report relating to research for clarifying the entity of the reducing effect of the free drug concentration has not been found yet. While, it can be considered that said reducing effect may appear, for example by a mechanism similar to the allosteric effect of an enzyme, and surprisingly, it was found that the binding affinity for the plasma protein could be increased by using the combination of the drugs shown in Example 8 of the present invention.
Regarding dose forms of the drug, in the case that the first drug and second drug are administered simultaneously without necessarily considering any chemical change such as decomposition thereof by mixing together, it is possible to supply a pharmaceutical product prepared by mixing the first drug with the second drug. In such a mixed-type of pharmaceutical preparation, medicinally acceptable ingredients, such as pH-adjusting agents, inorganic salts for adjusting the osmotic pressure, stabilizing agents for stabilizing each one of these ingredients may be added thereto. The mixed-type of pharmaceutical preparations can be processed into the suitable dose form, for example a liquid form preparation, a lyophilized form preparation and the like, in consideration of the constitutional ingredients, preservation stability thereof, etc.
Further, the first drug and the second drug may be supplied as a kit form in which they are filled in a container separately. Similar to the mixed-type preparation, medicinally acceptable ingredients, such as stabilizing agents or the like may be added to each one of these separate type of drugs, and in consideration of administeration method, stabilization and the like, these separate type of the drugs can be processed into the suitbale form of preparations, such as liquid form preparation, a lyophylized form preparation and the like.
In case of the kit form mentioned above, the first drug and the second drug can be administered separately, or can be administered simultaneously by mixing together at the time of use. Especially, in the case of predicting changes of quality of the product, such as decomposition of the ingredients during the storage after mixing the first drug and the second drug, and in the case that these drugs are administered by different route, or in the case that these drugs are administered necessarily in different timings, the above-mentioned kit form in which the first drug and the second drugs are filled in separate containers are 5 useful.
Generally, as the plasma proteins bound to drug, human serum albumin (HSA), al-acidic glycoprotein (AGP), 7-globulin, lipoprotein and the like are exemplified, and many drugs may bind to HSA or AGP.
10 In selecting the second drug, for example when the first drug has the property of mainly binding to HSA, it may be preferably selected from an acidic drug having the binding affinity for HSA. When the first drug has the property of binding to AGP, it may be preferably selected from a basic drug having the binding affinity for AGP. Further, in the case that the first drug has the affinity for plural plasma proteins or has the affinity for different binding sites on the single protein, the use of plural drugs as second drugs may be effective. Furthermore, in case of selecting the second drug, other properties than the binding affinity with the above-mentioned plasma protein should be considered, such as clinically acceptable appearance of the original pharmacological activity, a broad range of usual dose, and maintenance of high blood concentration after administration, etc.
Administration timing of the second drug may be either simultaneously with the first drug or before or after the administration of the first drug, thus the timing is selected suitably so as to obtain the effect to meet the administration purpose of the first drug.
Administration route of the drugs may be suitably selected from either one of intravenous injection, intraarterial injection, subcutaneous injection, lymphaginal injection or oral administration.
Specifically, HSA has three specific binding sites such as site I, site II and site III on its molecule. As the second drug with binding specificity at the site I, the following drugs can be exemplified;
bucolome (5-n-butyl-l-cyclohexyl-2,4,6-trioxoperhydropyrimidine), cefazolin (7-[i-(H)-tetrazolylacetamido]-3-[2-(5-methyl-1,3,4-thiazolyl)thiomethyl]-3-cephem-4-carboxylate), phenylbutazone (1,2-diphenyl-3,5-dioxo-4-n-butyl-pyrazolidine), valproic acid (sodium 2-propylpentanoate), aspirin (2-acetoxybenzoic acid), salicylic acid (0-hydroxybenzoic acid), ceftriaxone (disodium (6R,7R)-7-[2-amino-4-thiazoyl]-2-methoxyiminoacetamide)-3-(2,5-dihydro-2-methyl-6-oxide-5-oxo-1,2,4-triazin-3-ylthiomethyl)-8-oxo-5-thia-l-azobicyclo[4.2.0]octo-2-ene-2-carboxylate), sulfamethizol (N-(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylamide), canrenoic acid (17-hydroxy-3-oxo-17a -pregna-4,6-dien-21-carboxylate), dansyl-L-asparagine, etc. As the second drug with binding specificity at the site II, the following drugs can be exemplified;
ibuprofen (2-(4-isobutylphenyl)propionic acid), nabumetone (4-(6-methoxy-2-naphthyl)-2-butanone (6-methoxy-2-naphthylacetic acid, which is a metabolite of nabumetone, shows binding specificity at the site II) and probenecid (4-(N,N-dipropylsulfamoyl)benzoic acid), etc. Further, etoposide ((5S, 5aR, 8aR, 9S) -9- [ (4, 6, 0-(R)-ethylidene-R-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl-isobenzofuro[5,6-f][1,3]benzodioxol-6(5aH)-one) also has binding specificity for HSA, though the binding site on the HSA has not been assigned. As the second drug with binding specificity for AGP, the following drugs can be exemplified, disopyramide (a-(2-diisopropylaminoethyl)-a-phenyl-2-pyridineacetamide), verapamil (a-[3-[[2-(3,4-dimethoxyphenyl)ethyl]-methylamino]propyl]-3,4-dimethoxy-a-(1-methylethyl)benzeneacetonitrile) and propranolol(1-isopropylamino-3-(1-naphthyloxy)-2-propanol), etc.
As compounds, such as chelating group or recetor ligand, of radio-therapeutic drug for jz vivo use or radiodiagnostic drug for in vivo use, both having binding affinity for plasma protein and being labeled with radioactive nuclides, following compounds can be exemplified; mercaptoacetylglycylglycylglycine (MAG3) or its derivatives, hexamethylpropyleneaminoxime(HMPAO) or its derivatives, ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin) or its derivatives, 2,3-dimercaptosuccinic acid (DMSA) or its derivatives, ethylene cysteine dimer (ECD) derivatives such as N,N'-ethylene-L-cystein diethylester and the like, methoxyisobutylisonitrile (MIBI) derivatives, polyamine derivatives such as diethylenetriaminepentaacetic acid (DTPA) and the like, pyridoxylideneaminate derivatives such as pyridoxyleneisoleucine and the like; other chelating groups which can form complex with radioactive metals such as methylene diphosphonate (MDP), hydroxymethylene diphosphonate (HMDP) and the like; and compounds labeled with radioactive iodine such as /3-methyl-p-iodophenylpentadecanoic acid (BMIPP), N-isopropyl-p-iodoamphetamine (IMP), iodinated hippuric acid (OIH), 3-iodobenzylguanidine (MIBG), tropane derivatives such as N-(3-fluoropropyl)-2/3-carbomethoxy-313-(4-iodophenyl)nortropane (FP-CIT), N-methyl-213-carbomethoxy-3/3-(4-iodophenyl)nortropane (CIT) and the like.
As the radioactive nuclides, following nuclides can be exemplified; 11-carbon (11C), 15-oxygen (150) , 18-fluorine ('8F) , 32-phosphorus (32P) , 59-iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga) , 81m-krypton (81mKr) , 81-rubidium (81Rb) , 89-strontium (B9Sr) , 90-yttrium (50Y) , 99m-technetium (99mTc), 111-indium (111In) , 123-iodine (123I) , 125-iodine (125I) , 131-iodine (131I) , 133-xenon (133Xe) , 117m-tin (11'mSn), 153-samarium (153Sm) 186-rhenium ('86Re) , 188-rhenium (188Re) , 201-thallium (201T1) , 212-bismuth (212Bi) , 213-bismuth (213Bi) and 211-astatine (21 'At). As to the diagnostic purpose, 18-fluorine ('6F), 99m-technetium (99mTc), 67-gallium (17Ga) , 111-indium (111In) , 123-iodine (123I) , 131-iodine (131I) and the like are frequently used.
99m-Technetium complex of MAG3 (99mTc-MAG3) is a radiopharmaceutical for in vivo use and is widely used for the purpose of diagnosis of renopathy and uropathy, because it possesses accumulation property to the kidney. It is known that about 90% of 99mTc-MAG3 bind to plasma protein. For this reason, in vitro study was conducted by using 99mTc-MAG3 as the first drug, the serum as the plasma protein, wherein the blood cells and blood coagulation factors are removed, and several pharmaceuticals with the binding affinity for serum proteins as the second drug. As the result, when bucolome, valproic acid, warfarin or the like was added, then displacement of 99mTc-MAG3 occurred either in human serum albumin or in rat serum albumin, thus the free fraction of 59mTc-MAG3 in serum albumin increased. In case of bucolome, the free fraction of 99mTc-MAG3 particularly increased (Table 1). Fig. 5 shows time course of accumulation of 99mTc-MAG3 in the rat kidney after administering 20 mg/kg of Bucolome. Fig. 6 shows the biodistributions in rats at 10 minutes after the administration of 99mTc-MAG3. In this case, 10 minutes before the administration of 99mTc-MAG3, 100 mg/kg of bucolome was administered. These results show that the amount of free 99mTc-MAG3 was increased by bucolome loading, and rapid clearance from the blood and accumulation of 99mTc-MAG3 into the kidney took place.
Regarding 99m-technetium complex of diethyl ester of N,N'-ethylene-L-cystein (99mTc-ECD), which is a radiopharmaceutical used for scintigraphy of regional 5 cerebral blood flow, in the in vitro experiment by using a human serum, the displacement effect was observed by adding Etoposide (cf. Example 4 and Table 8).
For the purpose to prove the displacement effect on organic compounds, in vitro and in vivo 10 experiments were conducted by using N-isopropyl-p-iodoamphetamine (1z3I-IMP) as one example of organic compounds. In im vitro experiments, the displacement effects were observed by adding warfarin or 6-methoxy-2-naphthylacetic acid (6-MNA), both of which have the 15 specificity to HSA, or by adding verapamil which has the binding specificity to AGP (cf. Example 5 and Table 9), thus the displacement effect on organic compounds was observed and proved. Further, in the experiments by using 6-MNA and Verapamil in which those were added separately or added simultaneously, the synergistic effect of the displacement effect was observed, thus it is indicated that the displacement effect can be enhanced by using plural second drugs together (cf.
Example 6 and Table 10).
In in vivo experiments in rats, as compared with the control group (unloaded with verapamil), the higher concentration of free 123I-IMP in blood was observed in the test group (loaded with verapamil).
Reflecting the fact, 10 minutes after the administration, the brain uptake of 123I-IMP in the test group (loaded with verapamil) was about 2 times that in the control group (Example 7). In this ,fin vivo experiments, the test solution containig both of 123I-IMP
and verapamil was prepared in advance (Example 7 (1)) and used it in the experiment. Results of Example 7 indicates that it is possible to regulate the free drug concentration by simultaneous administration of the first and second drugs using their mixture as well as by the separate administration of the first drug and the second drugs and the biodistribution of the first drug could reflect it.
As for an example of the reducing effect of the free drug concentration, decrease in the free fraction (i.e., increase in binding fraction to protein) was observed in in vitro experiment using N-(3-fluoropropyl)-2Q-carbomethoxy-3Q-(4-iodophenyl)-nortropane labeled with radioactive iodine (1-125) (1251_ FP-CIT) together with human serum by adding dansyl-L-asparagine (DNSA) which is specific to the site I on albumin (cf. Example 8 and Table 15).
EXAMPLES
The present invention will be explained in more detail by illustrating the following examples, but the invention will not be restricted only to these examples.
- - - ---------- -Methods for testing the compounds obtained and the reagents used are as follows.
(1) Ultrafiltration: Filtration was conducted by using an equipment of ULTRACENT-10 which treats for up to 1.5 ml (manufactured by Tosoh Corp.).
(2) 99mTcO,-: Prepared by use of a 99Mo/99mTc generator of MEDITECH (manufactured by NIHON
MEDI-PHYSICS CO., LTD.) and used its eluent as in the form of a physiological saline solution.
(3) Reagents: The all reagents used were "Extra-pure reagent grade".
(4) Test animals: The all test animals used were Wister-strain male rats (body weight: 200-250g).
Prior to the test, the animals were breeded under light-dark cyclic condition in every 12 hours for 1 week, and had free access to food and water.
Example 1 Examination of displacement effects of the second druas on 99mTc-MAG3 binding to plasma protein Displacement test of 99mTc-MAG3 binding to serum albumin was conducted as follows by use of human serum or rat serum and site-specific drugs (second drugs) with binding affinity for the binding site I or site II on albumin. Bucolome, valproic acid, warfarin and cefazolin were used as site-specific drugs with binding affinity for the site I, and ibuprofen, sodium octanoate and sodium oleate were used as site-specific drugs with binding affinity for the site II.
First, albumin content in a normal human serum was measured previously, and the concentration of the human serum albumin (HSA) was adjusted to 500 /IM by phosphate buffer (pH=7.4).
Further, a site-specific drug with the binding affinity for the site I or the site II on HSA was added to the above-mentioned serum solution, as in the form of a methanol solution or an aqueous solution. As the sample solution for control group, only methanol or water was added to the above-mentioned serum solution.
Next, a certain amount of 99mTc-MAG3 (about 740 kBq/20 121) was added to each of the sample and a certain amount (20-50 121) of the sample was taken out as the specimen before ultrafiltration. Each 0.9 mL of the samples was put in a ultrafilter and conducted ultrafiltration under the condition of 1500 X g, for 10 minutes. Then, 20-50 11.1 each of the filtrates was taken out as the specimen after ultrafiltration.
Radioactivities (cpm) of the specimens before and after ultrafiltration were measured, and the free fraction (%) of 99mTc-MAG3 was calculated by the following equation:
free fraction of 99mTc-MAG, (%) = [A]/[B]
[A]: Radioactivity (cpm) after ultrafiltration, [B]: Radioactivity (cpm) before ultrafiltration Similarly, albumin content in normal rat serum was previously measured, and the concentration of the rat serum albumin (RSA) was adjusted to 375 UM by phosphate buffer (pH=7.4) so as to conduct the test similar to that of the case of human serum. The results are shown in Table 1, Fig.l and Fig.2.
In the case of human serum, the free fraction (%) of 99mTc-MAG3 in the test samples to which a site-specific drug to site I was added, such as bucolome, valproic acid, warfarin or cefazolin, was significantly increased as compared with the free fraction (10.2%) of 99mTc-MAG3 of the control sample.
On the other hand, in other test samples to which a site-specific drug to site II was added, such as ibuprofen, sodium octoate or sodium oleate, increase in the free fraction was not observed.
Similarly, in test samples of the rat serum to which a site-specific drug to site I was added, increase in the free fraction (%) of 99mTc-MAG3 was observed.
As can be seen from the above results, it is clearly indicated that the free fraction of 99mTc-MAG3 in the blood can be increased by adding a site-specific drug to site I. Although, warfarin, octanoic acid and oleic acid might be considered clinically unsuitable for the purpose of this invention, they were used for the confirmation of the effects of site-specific drugs to the binding site.
+ o\C OP o\C o\o o\o z~ Ln C) Co N
U) H 0 O 00 M N O I I
Pi 41 O M Ol M m U ~' N cf M M
(o r I t 0\0 u=) r I r1 o\C
M N
I N
U U) I o\C oW o\C o\o o\C
U Co [- Co CO
9 - ÃE- If' Ln ~t I I
(o i R+ i p N aD M CD CO
I~' N M (N M N N
U
(1) U) o\C o\C o\C o\o o\C o\o o\o C N r lD M
00 O t` O C l.f) CD w -T
Q' '- M M M IT O
v ' rI ci r-I ,-1 Ol Ol 4-i U
a 1 o\C
U o r-i 4-4 H b Of 4-4 O 4- O
O
o 0 a U) I. \o o\o o\o o\C o\C
U o\C OP
E CD
' (N (3) L r--1 to [~
U (f) b -1 r~ Oo N -i o rn ao a a N
U) a) U
rI
4-4 r4 H -H O I~ Z7 U U 0 =r-1 -r-I
U
U 4J ro N b co I~ r -H
(0 ~4 S a (1) U s~ =r-I 4) U U
Q1 CP -0 a--( r=-1 E -r=1 -ri r-1 4-4 -r-1 Ti U
(C) O 'O 0 (Ti 0 0 r- 0 U 4J O Q, 4-4 (Ti Q, (o -H
S~ s~ U r- 4-4 -P N
0 0 (0 (0 N A U r-I
U U A 3 U =r-1 0 0 Example 2 Bi odi stri buti on of 99mTc-MAG, in rat loaded with bucolome Effect of second drug on biodistribution of 99mTc-MAG3 in rat was examined using the control group and the test group with bucolome loading. 99mTc-MAG3 (740 kBq/100 LLl) was administered to the tail vein of Wister-strain rat. The rats were decapitated at 2, 5, and 15 minutes after administration of 99mTc-MAG3, then the blood and the organs of interest were excised.
10 After measured the weight of these orgams, the radioactivities were determined. After decay correction of the radioactivity, the accumulation ratios (% dose/
organ and % dose/g of the tissue) were determined.
As for the rat of test group loaded with bucolome, 5 minutes before the administration of 99mTc-MAG3, 20 mg/kg of body weight or 100 mg/kg of body weight of bucolome was administered to the tail vein.
The results are shown in Table 2 and Table 3 (control group), Table 4 and Table 5 (test group, loaded with 20 mg/kg of bucolome) and Table 6 (test group, loaded with 100 mg/kg of bucolome).
In the control group and test group with bucolome loading of 20 mg/kg of body weight, wherein the dose and other conditions were the same as mentioned above, except the decapitation time was prescribed at 2, 5 and 10 minutes, administrations and decapitations of rats were conducted so that 3-5 ml of blood per one rat were collected. Serum was separated using a sample tube, after that the free fraction was determined by the procedures as described in Example 1. The time course of the free fraction of 99mTc-MAG3 in vivo are shown in Fig. 4.
From the results shown above, it has become appearant that blood clearance was accelarated in the test group with bucolome loading (Fig. 3), and the free fraction of 99mTc-MAG3 in vivo in test group was remarkably increased (Fig. 4).
In the control group, accumulation of 99mTc-MAG3 in the kidney (% dose/organ) increased from 2 minutes to 5 minutes after the administration, then gradually decreased and disappeared. While, in test group with bucolome loading, accumulation of 99mTc-MAG3 in the kidney rapidly increased to the maximum value just after the administration (in 2 minutes), then decreased and disappeared quickly as compared with that of the control group (Fig. 5).
Biodistribution of 99mTc-MAG3 (% dose/g tissue) in rat 10 minutes after the administration is shown in Fig. 6. As can be seen from Fig. 6, in the test group with bucolome loading, 99mTc-MAG3 was rapidly cleared from the kidney which is the target organ of 99mTc-MAG3, thus radioactivity was quickly cleared as compared with that of the control group. Clearance from the blood and other organs were also rapid.
C) o c v' o 0 o O to l0 0 00 Ln N O 0 O N Cl O 0 r-i +1 +1 +1 +1 +1 +1 +1 +1 H c1 0 CO M 'IT C1 Cl E r-I M N N 0 M N '-1 (d O O -i Ol CO O r-i IzT
0) Ln ~-I r1 O O O O U) O O CO
O r-1 M
4) U) l0 O M C) 0) Co N N
0 U) O U7 V O) N N lqr lz~' a) C) O O O N O O O
4i 0\0 O O O O M O O t7 +1 +1 +1 +1 +1 +1 +1 +1 U a E Ln 'IT 0) r-1 00 0) Ln N
N CO '-i N Cil N N N
O O O O r-I l0 r-i O (N CO
4-4 O O Ol c; O lO
0 N r1 r-i O
0 -A M M Ol m to l0 -4 O
=-i W O -4 O T) v O lt' O O O N 0) 0 r-I 0) 4J rl U) O O O O O O O
+1 +1 +1 +1 +1 +1 +1 +1 a--I r 0) 0) N V lqr ;;r C) U) a--i H lfl N I'D CO (N CO 0) O
r-i O O r-i v -I M r-i U M
Lf) O O O LC) r O O .-I
O
ri i~
c =ri l0 r1 N Cl Cl l0 01 N N r-I Co 0 M "i r-I
N U) O O O M I'D O 1-4 ri J-) O O O O T O O O
r +1 +1 +1 +1 +1 +I +1 +1 H O N l0 l0 N N L() 110 (d I M N 0) CO l0 M M
H r i v- N r-I CO N Q0 N
N
O O O Lf) M O O O
N
U) u) a) U >1 0) U E N f~ H
tP r/-'~i C 0 (d > ZS >~ = ri H aD4 (0 41 = i =r N H4 0 co a co a x x a N ~O r O ~' N O N
U) N O O LU N N r1 if) O O O O O N O O
O O O O O r-1 O O
+1 +I +1 +1 +1 +1 +I +1 U) E O 110 co O O N N (N
U) l0 N I7' 1-4 O O L '-i rl ~f) -4 O O .-i r -I (N O r1 O O O O O 0o c; O
a) U) co CD ['N O 0i m -1 co 0 U) ri O N rI O l0 M O
'CS a) O O O O O N O O
.1J
o\o O O O O O N O O
1 +1 +1 +1 +1 +1 +1 +1 +1 U E N l0 In U-) 110 CO M
co Ol .-I N N r-i 0 O M CD CD O .-i Ln r1 (\J
C C C C C U C C
44 b~
O
O N co N I7' d O 1 l0 41 U) -1 O ri l0 m l0 =ri 4J ri O O O N dl O O
Q O C C C ) * O O
+1 +1 +1 +1 +1 +1 +1 +I
CD Q' O r-1 (n .--I O O
- U) l0 O Ln M (N N 0l [--.H (0 Ln T, 0 O O O O O O
O
m -H
1~ r1 Ol r1 r I d l0 O
U
M M N -I CO rn LU O
M 4--1 r1 O O O O r1 O r1 O O O O O M O O
ri +1 +1 +1 +1 +1 +1 +1 +1 (N .-i M l0 0) Ol CD r1 fly co N M r- N M 'IT N
E N V r1 N r-I Ln O c)' l0 r1 O O C C M O O
'-i U) U) a) U >1 N S-I (0 ~-I a) 4-1 (d 0 a) U E a) S-I t tT 0 r-I r~ 0 > C m r.
~4 r-1 Q.~ (0 41 -.-I = H a) 0 m Cl) a co a x x a Ln M M O N Ln U-) N
O Ln c' Co Ln N O
U) C) O O ri ) O O
a) co +1 +1 +1 +1 +1 +I +1 +1 ri c-i Ln c' to 0) Ln rn U) r N O O N OD l0 .4-) N O O r-i CO LC) O O Ol rd E Ln r-I O O O O Ol O O M
~4 0 N
rI U
Ol M N LI) N Ol N
U) O N M N 0) -1 N C) Q) 0 O O v' (N O O M
J--) : O O CD, c; CO O O lzT
U +1 +1 +I +1 +1 +1 +1 +1 CO O r-i N CO N CO N
(~ i lC) -i r-i r4 M 0) O 0) O O O -i N r-i O r-i N
L~4 -4 O O O O i N O O
o O
F m O r I U) W
= O M Ln [ Ql N r-i "o U) '-i O O M N M r-I M N
a) 00\0 O O O O O al O O N
4 +1 +1 +1 +1 +1 +1 +1 +1 -P tm H CO Ol m O N IT lO N
U ~' M if) U) r-I Ln 01 -1 to ' H C) r-i r-i r-i m -4 l0 O a) (0 O O O M N O O N
'H H 0 (N
'-i N N M M d' cl 0) O N Ln m 11:31 M C) cr U) U O O O M N O O ( r-+1 +I +1 +1 +1 +1 +1 +I
itl rl M Ol Ol 0) K' O N N
H E: O M CO CO O '-i ' C) r-i N N N T (N [`N co (N O O O N O O O O
N
U) U) a) U >1 b 4) U E; 4) 7-i tT ,~
C1 r=-I S' 0 / 'b m r~ =H
4--I Cl) (Ti 4-1 -,H r i N
0 ) a U) a x x a co 110 N N co M .--1 O
U) co O Ln .-i N N N N
a) CD O CD O CD OD O O
O O O O O -I O O
+1 +1 +1 +1 +1 +1 +1 +1 N co OD N co Ol Ln r-i Ln -1 CO M co O CT OD
Ln ~-i O O CD CD CO O O
O O O O O O O
U) -W N
m E O r-I r-I O Ln r r O, ~-1 O V) r ri (N (N Cn lO r i d --i a) O O CD O O OD O O
O
O O O O O M O O
+1 +1 +1 +1 +1 +1 +1 +1 Q rI O l) (N M r CO r O
00 N lO M .--1 Ln LO N
,x r-i c:) O O c-i Ln O .-I
U O
E U) O JJ M Ln r r r O r-i M
a-1 N ' CD -1 r--1 ,--1 lO N r O U) CD CD CD CD O N CD CD
O O O O O O O O
+1 +1 +1 +1 +1 +1 +1 +1 f-I -,-i v' (r) Ln M O O N C
ow r d' OD ~' M 00 Ln r r 0 Ln CD rl O N CD r-i m ~-1 S -I Ln a--1 O O O O O T-1 O O
U) co r co M '-I LO Ol M
O a) (d Ln -i r-i N Ch r C7 1-1 I H 0 CD O (D -I rI M O CD
CLl -i U) (D O O O O O O O O
= +1 +I +1 +1 +f +I +1 +1 Un O C I~zv Ln CU Ol m CU
=ri Ln Ln r-I c1' L(=) w N r QI O . 1 M c I co O U lD
A N i O O O O (4 O O
cU -1 Ei U) co O U >1 a) S i (0 $-1 a) -W
0 ((0 0 a+ 0 > b ~-i -i a (0 4J -H =ri a) 0 m U) QI Cl) a x x a Table 6. Biodistribution of 9 Tc-MAG3 in rats minutes after the administration (Test group with 100 mg/kg bucolome loading: % dose/g tissue) Control group Test group Organs with bucolome loading Blood 0.317 0.073 0.047 0.044 Brain 0.010 0.001 0.001 0.001 Spleen 0.052 0.008 0.009 0.008 Pancreas 0.046 0.000 0.006 0.007 Stomach 0.024 0.024 0.040 0.036 Liver 0.151 0.001 0.033 0.026 Kidney 6.191 0.187 0.651 0.324 Heart 0.101 0.016 0.014 0.010 Lung 0.195 0.030 0.043 0.037 5 Example 3 Examination of displacement effect on 99mTc-MAG., by means of renography in rats By using Wistar-strain rats (body weight:
400g), displacement effect of bucolome on 99mTc-MAG3 was 10 examined by means of renography in rats. Prism 3000 (picker) was used as an apparatus.
A catheter was inserted into the femoral vein of the rat, then 99mTc-MAG3 (11.1 MBq) was injected through the catheter and the control renogram was obtained. The dynamic imaging was conducted 10 seconds/scan for 20 minutes. About 2 hours after, confirming the urination and decrease in background radioactivity, then bucolome was loaded to the same rat.
Bucolome was dissolved in ethanol and adjusted as in the dose of 20 mg/kg, then intravenously injected by using a microinjector taken in 10 minutes. About 5 minutes after finish of the intravenous injection of bucolome, 99mTc-MAG3 was intravenously injected through the catheter and the renogram was taken similarly by 10 seconds/scan for 20 minutes. Fig. 7 shows the renogram (time-radioactivity curves in the kidney) used for functional analysis of the kidney. As can be seen from the Fig. 7, in the control group, the radioactivity curve went up gradually at the initial stage after the administration, and the peak time was 240 seconds. On the other hand, in the test group with bucolome loading, the radioactivity curve rose quickly, and the peak time was 120 seconds which was a half length of that of the control group. Renal function is usually analyzed by determination of the peak time in this renogram and a slope of the straight line in a linear regression. By inhibiting the binding ability of 99mTc-MAG3 to plasma protein, the renogram was obtained as close to an ideal and was apploximated to a simple curve. Thus, the functional analysis of the kidney can be easily carried out, and the time for functional analysis can be shortened by shortening the peak time.
Table 7. Analytical results of renogram of 99mTc-MAG3 in rats Peak time Slope (Second) (Count/second) Rat 1 Control group 240 1.166 Test group (with bucolome loading) 110 2.208 Rat 2 Control group 170 0.941 Test group (with bucolome loading) 120 2.000 Example 4 Examination of displacement effects of the second drugs on 99mTc-EDC binding to plasma protein Displacement experiment of 99mTc-ECD binding to a serum albumin was conducted by procedures similar to 5 those shown in Example 1 using human serum; and bucolome, valproic acid, warfarin and cefazolin with binding specificity to the site I on albumin; ibuprofen and sodium octanoate with binding specificity to the site II on alubumin; and etoposide with binding 10 specificity to HAS on which binding site is not identified. The results are shown in Table 8.
As compared with the free fraction (26.03%) of 99mTc-ECD in human serum shown in control group, the free fraction of 99mTc-ECD in human serum were remarkably 15 increased in test group by etoposide, both at the concentration of 200 9M and 400 4M. Similarly, the free fraction of 99mTc-ECD in human serum were also incresed by bucolome, valproic acid and warfarin, but were not remarkably shown as compared with that of 20 etoposide. On the contrary, the free fraction of 99mTc-ECD in human serum were not clearly increased by ibuprofen and sodium octanoate which have the specificity to the site II on albumine.
Table 8 Displacement of 99mTc-ECD binding to plasma protein Site-specific free fraction of drug 99mTc-ECD ( % ) (second drug) Concentration 200 u M 400 gm Control 26.03%
Bucolome 28.62% 30.25%
Valproic acid 28.36% 30.250 Warfarin 31.00% 31.37%
Cefazolin 25.92% 27.40%
Etoposide 33.26% 37.38%
Ibuprofen 23.09% 24.09%
Octanoic acid 28.22% 29.64%
Example 5 Examination of displacement effects of the second drug on 123I-IMP binding to plasma protein Displacement experiment of 123I-IMP binding to a serum albumin was conducted by procedures similar to those shown in Example 1 using human serum; and as the second drug, bucolome and warfarin with binding specificity to the binding site I on albumin; ibuprofen, sodium octanoate, 6-methoxy-2-naphthylacetic acid (6-MNA) with binding specificity to the binding site II on alubumin; and verapamil which has the specificity to al-acid glycoprotein (AGP). Concentration of the second drug (e.g., bucolome) was 400 4M and added amount of 1231-IMP was about 220 kBq/20 9L. The results are shown in Table 9.
As compared with free fraction (29.29%) of 1231-IMP in human serum shown in control group, the free fraction of 123I-IMP in human serum in test group was remarkably incresed by adding verapamil with binding specificity to AGP. Further, the free fraction of 1231-IMP binding in human serum in test group was also increased by warfarin and 6-MNA mainly bound to albumin.
In view of these facts, it is suggested that 1231-IMP
binds to the binding site on both albumin and AGP, and it is clearly understood that the free fraction of 123I-IMP can be increased by a drug having the specificity to each binding sites of these proteins.
Table 9. Displacement of 1231-IMP binding to human plasma protein (Concentration of the site-specific drug was 400u M) Site-specific drug free of fraction of 123I-IMP (%) (second drug) Control 29.29%
bucolome 30.26%
warfarin 34.69%
ibuprofen 28.43%
octanoic acid 28.74%
METHOD OF THE ADMINISTRATION OF DRUGS HAVING
BINDING AFFINITY WITH PLASMA PROTEIN AND
PREPARATION TO BE USED IN THE METHOD
TECHNICAL FIELD
The present invention relates to a method of the administration of drugs with binding affinity for plasma protein and drugs regulating the effective ingredient dose of drugs with binding affinity for plasma protein; and a pharmaceutical preparation whereby the effective ingredient dose of drugs with binding affinity for plasma protein is regulated.
BACKGROUND ART
Generally, drugs administered for the purpose of medical treatment or diagnosis once go through the systemic blood circulation, and then take the process of absorption, distribution, metabolism, excretion and the like. In the process of absorption and distribution, the drug moves along on flow of the blood, while it transfers to each spaces of intravascular, interstice and intracellular by diffusion and transportation of a free drug being in the state of unbound form with proteins, and finally the drug arrives at the active region of target.. When movement of the drug reaches a steady state, then the free drug concentration in each space become uniform, thus the whole pattern of the concentration of the drug is determined by the binding level with proteins. Hence, in accordance with the property, a drug in vivo, may partially exists in the form of reversible binding state with biopolymers such as plasma proteins. Generally, drugs permeable through capillary wall or cell membrane are free drugs, therefore, the transfer of such free drugs being unbound with plasma proteins to the active region of target may be greatly influenced by the binding level with plasma proteins.
For example, mercaptoacetylglycylglycylglycine labeled with 99m-technetium (99mTc-MAG3) is widely used in renal scintigraphy, especially the renal plasma flow can be effectively exhibited by its efficient renal extraction and renal tubular secretion. It is known that about 90% of 99mTc-MAG3 binds to plasma protein in an ordinary clinical dose (Bubeck B. et al., J. Nucl.
Med., -U, 1285-1295, 1990). If the binding of 99mTc-MAG3 with plasma protein is inhibited by drugs having high binding affinity to the same binding site on protein with 99mTc-MAG3, then more clear renal imaging can be obtained in the earlier stage after the administration, thus it may be thought that the dose of radioactivity to the patient can be reduced at the same time.
On the contrary, if the binding of drugs with plasma protein is increased, then the concentration of the free drugs in the blood can be kept in lower level for long period, therefore, it may be possible to achieve continuous appearance of pharmacological effects.
However, at the present stage, little is known as the research work for improving therapeutic effect or diagnostic effect of the drugs by regulating the concentrations of the free drugs, using the binding affinity of the second drug with plasma proteins.
DISCLOSURE OF THE INVENTION
In consideration of the above-mentioned problems, an object of the present invention is to provide a suitable method of the administration of drugs by regulating the binding affinity of the drug for plasma proteins, and at the same time, to provide a pharmaceutical preparation whereby the binding affinity of the drug for plasma protein can be regulated.
According to the present invention, the suitable administration of the drugs can be achieved by regulating the binding affinity of the drug for plasma protein, and at the same time, a pharmaceutical preparation for such administration can be provided.
The present invention relates to a method of administration of drugs with binding affinity for plasma protein, characterized by regulating the binding affinity of the first drug for plasma protein, when administering the first drug with the binding affinity for plasma protein, the second drugs, which have the binding affinity for the same plasma protein, for which the first drug has binding affinity, is administered simultaneously with the first drug or before or after the administration of the first drug.
Particularly, in the case of regulating the binding affinity of the first drug for plasma protein, it is preferable that the first drug and the second drugs bind to the same binding sites on the plasma protein. Further, the second drug may be administered before, after or simultaneously with the administration of the first drug, and such administration timing of the second drug can be suitably selected in connection with the timing when the free drug concentration of the first drug reaches to the level so as to obtain an adequate effect. Additionally, a single drug may be used as the second drug, or plural drugs may be used as the second drugs when synergistic effect can be expected.
In case of administering the first drug and the second drug simultaneously, the pharmaceutical preparations comprising the first drug and the second drug may be supplied. Further, the first drug and the second drug may be filled in a container separately, and may be supplied as a kit form. In case of such a kit form with separate containers, they may be administered simultaneously by mixing it together when used, or each one of the first drug and the second drug can be administered in different times separately or by different route. Furthermore, both of or either one of these first and second drugs may be commercially available pharmaceuticals.
When the first drug is radiodiagnosic agent for j vivo use or radiotherapeutic drug for im vivo use, the radioactive nuclides can be selected from the 5 group comprising 11-carbon (11C), 15-oxygen (150), 18-fluorine, (18F) , 32-phosphorus (32P) , 59-iron (57Fe) , 67-copper (67Cu) , 67-gallium (67Ga) , 81m-krypton ("'Kr) , 81-rubidium (81Rb) , 89-strontium (B9Sr) , 90-yttrium (90Y) , 99m-technetium (95m'Tc) , 111-indium (111In) , 123-iodine (123I) , 125-iodine (125I) , 131-iodine (131I) , 133-xenon (133Xe) , 117m-tin (117 iSn) , 153-samarium (153Sm) , 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (2O1T1) , 212-bismuth (212Bi) , 213-bismuth (213Bi) and 211-astatine (211At) .
In this case, compounds, such as chelating group or receptor ligand, of the first drug labeled with the above-mentioned nuclides can be selected from bisaminothiol or its derivatives, monoaminomonoamidobisthiol or its derivatives, bisamido-bisthiol or its derivatives, mercaptoacetylglycylglycyl-glycine or its derivatives, hexamethylpropylene-amineoxime or its derivatives, ethylenebis[bis(2-ethoxyethyl)phosphine](tetrofosmin) or its derivatives, 2,3-dimercaptosuccinic acid or its derivatives, ethylenecysteine dimer derivatives, methoxyisobutylisonitrile derivatives, polyamine derivatives, pyridoxylydeneaminate derivatives, methylene diphosphonate, hydroxymethylene diphodphonate 1 j derivatives, 13-methyl-co-phenylpentadecanoic acid or its derivatives, N-isopropyl-amphetamine, hippuric acid, benzylguanidine, tropane derivatives and the like.
The second drug may be selected from, for example, bucolome, cefazolin, etoposide, phenylbutazone, aspirine, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-2-naphtyl acetic acid, ibuprofen, probenecid, dan.syl-L-asparagine -(DNSA), verapamil or disopyramide and the like.
According to one aspect of the invention there is provided use, in the manufacture of a medicament, of:
a first drug having a binding affinity for a plasma protein;
wherein the first drug is a radiotherapeutic drug having a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150) , 18-fluorine, ('8F) , 32-phosphorus (32P) , 59-iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga) , 81:m-krypton (81mKr) , 81-rubidium (81Rb) 89-strontium (89Sr) , 90-yttrium (90Y) , 99m-technetium (99mTc), 111-indium ("'In), 123-iodine (1211) , 125-iodine (12.51) , 131-iodine (1311) , 133-xenon (133Xe) , 117m-tin (11'mSn) , 153-samarium (153Sm) , 186-rhenium (186Re) , 188-rhenium (188Re) , 201-thallium (201T1) , 212-bismuth (212Bi) , 213-bismuth (213Bi) or 211-astatine (211At) ; and wherein the binding group of the first drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a 6a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a P-methyl-w-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and a second drug having a binding affinity for the plasma protein;
wherein the second drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the second drug binds to the plasma protein, thereby decreasing the binding of the first drug to the plasma protein.
According to a further aspect of the invention there is provided use, in the manufacture of a medicament, of:
a first drug having a binding affinity for a plasma protein;
wherein the first drug is a radiotherapeutic drug having a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150) , 18-fluorine, (18F) , 32-I I I
Erb phosphorus (32P) , 59--iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga), 81m-krypton (elmKr), 81-rubidium (81Rb) , 89-strontium (89Sr) , 90-yttrium (90Y) , 99m-technetium (99' Tc) , 111-indium (111In) , 123-iodine (1231) , 125-iodine (125I) 131-iodine (1311) , 133-xenon (133Xe) , 117m-tin (117mSn) , 153-samarium (153Sm) , 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201T1) , 212-bismuth (212Bi) , 213-bismuth (213Bi) or 211-astatine (2"At) ; and wherein the binding group of the first drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a (3-methyl-6)-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and a second drug having a binding affinity for the plasma protein;
wherein the second drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the second drug binds to the plasma protein, thereby increasing the binding of the first drug to the plasma protein.
According to another aspect of the invention there is provided use, in the manufacture of a medicament, of:
a drug having a binding affinity for the plasma protein;
wherein the drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
wherein the drug is formulated for administration either before or after a radiotherapeutic drug having a binding affinity for a plasma protein;
wherein the radiotherapeutic drug has a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150), 18-fluorine, (18F) , 32-phosphorus (32P) , 59-iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga) , 81m-krypton (81mKr), 81-rubidium (81Rb) 89-strontium (89Sr) , 90-yttrium (90Y) , 99m-technetium (99mTC) , 111-indium (111In) , 123-iodine (1231) , 125-iodine (1252) , 131-iodine (1311) , 133-xenon (133Xe) , 117m-tin (117mSn) , 153-samarium (153Sm) , 186-rhenium (186Re) , 188-rhenium (188Re) , 201-thallium (201T1) , 212-bismuth (212Bi) , 213-bismuth (213Bi) or 211-astatine (211At) ; and wherein the binding group of the radiotherapeutic drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a 6d mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a R-methyl-w-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and whereby the drug binds to the plasma protein, thereby decreasing the binding of the radiotherapeutic drug to the plasma protein.
According to yet another aspect of the invention there is provided use, in the manufacture of a medicament, of:
a drug having a binding affinity for the plasma protein;
wherein the drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
wherein the drug is formulated for administration either before or after a radiotherapeutic drug having a binding affinity for a plasma protein;
wherein the radiotherapeutic drug has a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150) , :L8-fluorine, (18F) , 32-6e phosphorus (32P) , 59--iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga) , 81m-krypton (81mKr), 81-rubidium (81Rb) , 89-strontium (89Sr) , 90-yttrium (90Y) , 99m-technetium (99mTc) , 111-indium (111In) , 123-iodine (123I) , 125-iodine (125I) , 131-iodine (131I) , 133-xenon (133Xe) , 117m-tin (117mSn) , 153-samarium (153Sm) , 186-rhenium (186Re) , 188-rhenium (188Re) , 201-thallium (201T1) , 212-bismuth (212131) , 213-bismuth (213Bi) or 211-astatine (211At) ; and wherein the binding group of the radiotherapeutic drug is a bisaminothiol, a monoaminomonoamidobisth.iol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin), a 2,3-dimercaptosuccinic acid., an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a (i-methyl-ca-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and whereby the drug binds to the plasma protein, thereby increasing the binding of the radiotherapeutic drug to the plasma protein.
According to still another aspect of the invention there is provided a pharmaceutical composition for decreasing the binding of a first drug to plasma protein, which comprises:
1'o f a first drug having a binding affinity for plasma protein;
wherein the first drug is a radiotherapeutic drug having a binding group being labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150) , 18-fluorine, (18F) , 32-phosphorus (32P) , 59-iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga) , 81m-krypton (81mKr), 81-rubidium (81Rb) , 89-strontium (89Sr) , 90-yttrium (90Y) , 99m-technetium (99mTC), 111-indium ("1In), 123-iodine (1231) , 125-iodine (1211) , 131-iodine (131I) , 133-xenon (133Xe) , 117m-tin (117mSn) , 153-samarium (153Sm) , 186-rhenium (186Re) , 188-rhenium (188Re ) 201-thallium (201T1) , 212-bismuth (212Bi) , 213-bismuth (213Bi) or 21.1-astatine (211At) ; and wherein the binding group of the first drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropylenea.mineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a 1i-methyl-w-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and 6g at least one second drug having a binding affinity for the plasma protein;
wherein the at least second drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the at least one second drug binds to the plasma protein, thereby decreasing the binding of the first drug to the plasma protein.
According to a further aspect of the invention there is provided a pharmaceutical composition for increasing the binding of a first drug to the plasma protein, which comprises:
a first drug having a binding affinity for plasma protein;
wherein the first drug is a radiotherapeutic drug having a binding group being labeled with a radioactive nuclide:
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150) , 18-fluorine, ('8F) , 32-phosphorus (32P) , 59=-iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga), 81m-krypton (81mKr), 81-rubidium (81Rb) , 89-strontium (89Sr) , 90-yttrium (90Y), 99m-technetium (99mTc) , 111-indium (111In) , 123-iodine (1231) , 125-iodine (1251) , 131-iodine (131I) , 133-xenon (133Xe) , 117m-tin (117mSn), 153-samarium (153Sm) , 186-rhenium (186Re) , 188-rhenium (188Re), 201-thallium (201T1) , 212-bismuth (212Bi) , 213-bismuth (213Bi) or 211-astatine (211At) ; and 6h wherein the binding group of the first drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-et:hoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dieter derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a R-methyl-w-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and at least one second drug having a binding affinity for the plasma protein;
wherein the at least second drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the at least one second drug binds to the plasma protein, thereby increasing the binding of the first drug to the plasma protein.
According to another aspect of the invention there is provided a kit for non-medical diagnostic imaging, the kit comprising:
a first container containing a first substance having a binding affinity for plasma protein;
wherein the first substance is a radiodiagnostic substance having a binding group labeled with a radioactive nuclide:
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (15C)) , 18-fluorine, (18F) , 32-phosphorus (32P) , 59-iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga) , 81m-krvpton (81mKr) , 81-rubidium (81Rb), 89-strontium (89Sr) , 90-yttrium (90Y) , 99m-technetium (99mTc) , 111-indium ("1In) , 123-iodine (1231) , 125-iodine (1.251) , 131-iodine (1311) , 133-xenon (133Xe) , 117m-tin (117mSn) , 153-samarium (153Sm) , 186-rhenium (186Re) , 188-rhenium (188Re) , 201-thallium (201T1) ,. 212-bismuth (212Bi) , 213-bismuth (213Bi) or 211-astatine (211At) ; and wherein the binding group of the first substance is a bisarninothiol, a monoaminomonoamidob:Lsthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dieter derivative, a methoxyisobutylison_Ltrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a [3-methyl-ca-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and Eli a second container containing a second substance having a binding affinity for the plasma protein;
wherein the second substance is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
together with written instructions for their use for non-medical diagnostic imaging;
whereby the second substance binds to the plasma protein, thereby decreasing or increasing the binding of the first substance to the plasma protein.
According to yet another aspect of the invention there is provided use, in the manufacture of a diagnostic composition, of:
a first substance having a binding affinity for a plasma protein;
wherein the first substance is a radiodiagnostic having a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150) , 18-fluorine, (18F) , 32-phosphorus (32P) , 59--iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga) , 8:1m-krypton (81mKr) , 81-rubidium (81Rb) 89-strontium (89Sr) , 90-yttrium (90Y) , 99m-technetium (99mTc) , 111-indium (111In) , 123-iodine (1231) , 125-iodine (1251) , 131-iodine (1311) , 133-xenon (133Xe) , 117m-tin (117mSn) , 153-samarium (153Sm) , 186-rhenium (186Re) , 188-rhenium. (188Re) , Ei k 201-thallium (201T1) , 212-bismuth (212Bi) , 213-bismuth (213Bi) or 21_1-astatine (211At) ; and wherein the binding group of the first substance is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a (3-methyl-W-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and a second substance having a binding affinity for the plasma protein;
wherein the second substance is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the second substance binds to the plasma protein, thereby decreasing the binding of the first substance to the plasma protein.
According to still another aspect of the invention there is provided use, in the manufacture of a diagnostic composition, of:
6l a first substance having a binding affinity for a plasma protein;
wherein the first substance is a radiodiagnostic drug having a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150) , 18-fluorine, (18F) , 32-phosphorus (32P) , 59-iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga) , 81m-krypton (81mKr) , 81-rubidium (81Rb) , 89-strontium ("Sr) , 90-yttrium (90Y) , 99m-technetium (99mTc) , 111--indium (111In) , 123-iodine (123I) , 125-iodine (1251) , , 131-iodine (1311) , 133-xenon (133Xe) , 117m-tin (117mSn) , 153-samarium (153Sm) , 186-rhenium (186Re) , 188-rhenium (188Re) , 201-thallium (201T1) , 212-bismuth (212Bi) , 213-bismuth (213Bi) or 211-astatine (211At) ; and wherein the binding group of the first substance is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative,, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a 13-methyl-w-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and I 1 I i . I I
6m a second substance having a binding affinity for the plasma protein;
wherein the second substance is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the second substance binds to the plasma protein, thereby increasing the binding of the first substance to the plasma protein.
According to a further aspect of the invention there is provided use, in the manufacture of a diagnostic agent, of:
a substance having a binding affinity for the plasma protein;
wherein the substance is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
wherein the substance is formulated for administration either before or after a radiodiagnostic substance with binding affinity for a plasma protein;
wherein the radiodiagnostic substance has a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150) , 18-fluorine, (18F) , 32-phosphorus (32P) , 59=-iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga) , 8:1m-krypton (81mKr), 81-rubidium 6n (81Rb) 89-strontium (89Sr) , 90-yttrium (90Y) , 99m-technetium (99mTC) , 111-indium (1111n) , 123-iodine (1231) , 125-iodine (125I) , 131-iodine (1311) , 133-xenon (133Xe) , 117m-tin (117mSn) , 153-samarium (153Sm) , 186-rhenium (186Re) , 188-rhenium (188Re), 201-thallium (201Tl) , 212-bismuth (212Bi) , 213-bismuth (213Bi) or 21.1-astatine (21 'At); and wherein the binding group of the radiodiagnostic substance is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a (3-methyl-(z-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and whereby the substance binds to the plasma protein, thereby decreasing the binding of the radiodiagnostic substance to the plasma protein.
According to a further aspect of the invention there is provided use, in the manufacture of a diagnostic agent, of:
a substance having a binding affinity for the plasma protein;
6o wherein the substance is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
wherein the substance is formulated for administration either before or after a radiodiagnostic substance with binding affinity for a plasma protein;
wherein the radiodiagnostic substance has a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150) , 18-fluorine, (18F) , 32-phosphorus (32P) , 59-iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga), 81m-:krypton (81mKr), 81-rubidium (81Rb) , 89-strontium (89Sr) , 90-yttrium (90Y) , 99m-technetium (99mTc) , 111--indium (111In) , 123-iodine (1231) , 125-iodine (125I) , 131-iodine (131I) , 133-xenon (133Xe) , 117m-tin (117mSn) , 153-samarium (153Sm) , 186-rhenium (186Re) , 188-rhenium (188Re) , 201-thallium (201T1) , 212-bismuth (212Bi) , 213-bismuth (213Bi) or 211-astatine (21 'At); and wherein the binding croup of the radiodiagnostic substance is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative,, a pyridoxylydene aminate derivative, a methylene diphosphonate, a 6p hydroxymethylene diphosphonate derivative, a (3-methyl-w-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof;and whereby the substance binds to the plasma protein, thereby increasing the binding of the radiodiagnostic substance to the plasma protein.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 shows the free fraction of 99mTc-MAG3 in human plasma in the presence of site specific agent.
Fig. 2 shows the free fraction of 99mTc-MAG3 in rat plasma in the presence of site specific agent.
Fig. 3 shows the effect of bucolome on blood clearance of 99mTc-MAG3 in rat.
Fig. 4 shows the effect of bucolome on the free fraction of 95mTc-MAG3 in rat blood after administration of bucolome.
Fig. 5 shows the effect of bucolome on the accumulation of 95mTc-MAG3 in rat kidney after administration of bucolome.
Fig. 6 shows the effect of bucolome loading on the biodistribution of 99mTc-MAG3 in rat. mm 1c-MAG3 in rat.
Fig. 7 shows the renogram of 99mm BEST MODE FOR CARRYING OUT OF THE INVENTION
When the second drug having high binding affinity for the same plasma protein, for which the first drug has binding affinity, is administered simultaneously with the first drug, or before or after the administration of the first drug, then competitive displacement will take place at the binding site, thus it can be thought that the first drug may be released in a higher concentration (displacement effect).
Therefore, it can be expected that the higher pharmacological activity of the first drug can be obtained as compared with the case that the first drug is administered singly. On the contrary, when the binding fraction of the first drug to plasma protein increases by the effect of the second drug (reducing effect of the free drug concentration), continuous appearance of pharmacological effect of the first drug can be expected to achieve by keeping the free fraction of the first drug in blood at a lower level for long period.
In the present invention, the first drug with binding affinity for plasma protein may be either one of therapeutic agent or diagnostic agent, as long as it meets the purpose of administration.
Regardless of therapeutic or diagnostic purpose, in case of obtaining the above-mentioned displacement effect, the second drug may be preferably selected from those having competitive binding affinity for the same plasma protein as the first drug has;
increasing the free fraction of the first drug by the binding inhibition of the first drug with plasma protein; having the affinity for the same binding site of the first drug on plasma protein; and having the higher binding affinity for plasma protein.
On the contrary, in case of obtaining the above-mentioned reducing effect of the free drug concentration, the object is achieved by selecting the second drug from those having effect to increase the binding affinity of the first drug for plasma protein by the second drug bound to the same plasma proteins.
At the present, a report relating to research for clarifying the entity of the reducing effect of the free drug concentration has not been found yet. While, it can be considered that said reducing effect may appear, for example by a mechanism similar to the allosteric effect of an enzyme, and surprisingly, it was found that the binding affinity for the plasma protein could be increased by using the combination of the drugs shown in Example 8 of the present invention.
Regarding dose forms of the drug, in the case that the first drug and second drug are administered simultaneously without necessarily considering any chemical change such as decomposition thereof by mixing together, it is possible to supply a pharmaceutical product prepared by mixing the first drug with the second drug. In such a mixed-type of pharmaceutical preparation, medicinally acceptable ingredients, such as pH-adjusting agents, inorganic salts for adjusting the osmotic pressure, stabilizing agents for stabilizing each one of these ingredients may be added thereto. The mixed-type of pharmaceutical preparations can be processed into the suitable dose form, for example a liquid form preparation, a lyophilized form preparation and the like, in consideration of the constitutional ingredients, preservation stability thereof, etc.
Further, the first drug and the second drug may be supplied as a kit form in which they are filled in a container separately. Similar to the mixed-type preparation, medicinally acceptable ingredients, such as stabilizing agents or the like may be added to each one of these separate type of drugs, and in consideration of administeration method, stabilization and the like, these separate type of the drugs can be processed into the suitbale form of preparations, such as liquid form preparation, a lyophylized form preparation and the like.
In case of the kit form mentioned above, the first drug and the second drug can be administered separately, or can be administered simultaneously by mixing together at the time of use. Especially, in the case of predicting changes of quality of the product, such as decomposition of the ingredients during the storage after mixing the first drug and the second drug, and in the case that these drugs are administered by different route, or in the case that these drugs are administered necessarily in different timings, the above-mentioned kit form in which the first drug and the second drugs are filled in separate containers are 5 useful.
Generally, as the plasma proteins bound to drug, human serum albumin (HSA), al-acidic glycoprotein (AGP), 7-globulin, lipoprotein and the like are exemplified, and many drugs may bind to HSA or AGP.
10 In selecting the second drug, for example when the first drug has the property of mainly binding to HSA, it may be preferably selected from an acidic drug having the binding affinity for HSA. When the first drug has the property of binding to AGP, it may be preferably selected from a basic drug having the binding affinity for AGP. Further, in the case that the first drug has the affinity for plural plasma proteins or has the affinity for different binding sites on the single protein, the use of plural drugs as second drugs may be effective. Furthermore, in case of selecting the second drug, other properties than the binding affinity with the above-mentioned plasma protein should be considered, such as clinically acceptable appearance of the original pharmacological activity, a broad range of usual dose, and maintenance of high blood concentration after administration, etc.
Administration timing of the second drug may be either simultaneously with the first drug or before or after the administration of the first drug, thus the timing is selected suitably so as to obtain the effect to meet the administration purpose of the first drug.
Administration route of the drugs may be suitably selected from either one of intravenous injection, intraarterial injection, subcutaneous injection, lymphaginal injection or oral administration.
Specifically, HSA has three specific binding sites such as site I, site II and site III on its molecule. As the second drug with binding specificity at the site I, the following drugs can be exemplified;
bucolome (5-n-butyl-l-cyclohexyl-2,4,6-trioxoperhydropyrimidine), cefazolin (7-[i-(H)-tetrazolylacetamido]-3-[2-(5-methyl-1,3,4-thiazolyl)thiomethyl]-3-cephem-4-carboxylate), phenylbutazone (1,2-diphenyl-3,5-dioxo-4-n-butyl-pyrazolidine), valproic acid (sodium 2-propylpentanoate), aspirin (2-acetoxybenzoic acid), salicylic acid (0-hydroxybenzoic acid), ceftriaxone (disodium (6R,7R)-7-[2-amino-4-thiazoyl]-2-methoxyiminoacetamide)-3-(2,5-dihydro-2-methyl-6-oxide-5-oxo-1,2,4-triazin-3-ylthiomethyl)-8-oxo-5-thia-l-azobicyclo[4.2.0]octo-2-ene-2-carboxylate), sulfamethizol (N-(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylamide), canrenoic acid (17-hydroxy-3-oxo-17a -pregna-4,6-dien-21-carboxylate), dansyl-L-asparagine, etc. As the second drug with binding specificity at the site II, the following drugs can be exemplified;
ibuprofen (2-(4-isobutylphenyl)propionic acid), nabumetone (4-(6-methoxy-2-naphthyl)-2-butanone (6-methoxy-2-naphthylacetic acid, which is a metabolite of nabumetone, shows binding specificity at the site II) and probenecid (4-(N,N-dipropylsulfamoyl)benzoic acid), etc. Further, etoposide ((5S, 5aR, 8aR, 9S) -9- [ (4, 6, 0-(R)-ethylidene-R-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl-isobenzofuro[5,6-f][1,3]benzodioxol-6(5aH)-one) also has binding specificity for HSA, though the binding site on the HSA has not been assigned. As the second drug with binding specificity for AGP, the following drugs can be exemplified, disopyramide (a-(2-diisopropylaminoethyl)-a-phenyl-2-pyridineacetamide), verapamil (a-[3-[[2-(3,4-dimethoxyphenyl)ethyl]-methylamino]propyl]-3,4-dimethoxy-a-(1-methylethyl)benzeneacetonitrile) and propranolol(1-isopropylamino-3-(1-naphthyloxy)-2-propanol), etc.
As compounds, such as chelating group or recetor ligand, of radio-therapeutic drug for jz vivo use or radiodiagnostic drug for in vivo use, both having binding affinity for plasma protein and being labeled with radioactive nuclides, following compounds can be exemplified; mercaptoacetylglycylglycylglycine (MAG3) or its derivatives, hexamethylpropyleneaminoxime(HMPAO) or its derivatives, ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin) or its derivatives, 2,3-dimercaptosuccinic acid (DMSA) or its derivatives, ethylene cysteine dimer (ECD) derivatives such as N,N'-ethylene-L-cystein diethylester and the like, methoxyisobutylisonitrile (MIBI) derivatives, polyamine derivatives such as diethylenetriaminepentaacetic acid (DTPA) and the like, pyridoxylideneaminate derivatives such as pyridoxyleneisoleucine and the like; other chelating groups which can form complex with radioactive metals such as methylene diphosphonate (MDP), hydroxymethylene diphosphonate (HMDP) and the like; and compounds labeled with radioactive iodine such as /3-methyl-p-iodophenylpentadecanoic acid (BMIPP), N-isopropyl-p-iodoamphetamine (IMP), iodinated hippuric acid (OIH), 3-iodobenzylguanidine (MIBG), tropane derivatives such as N-(3-fluoropropyl)-2/3-carbomethoxy-313-(4-iodophenyl)nortropane (FP-CIT), N-methyl-213-carbomethoxy-3/3-(4-iodophenyl)nortropane (CIT) and the like.
As the radioactive nuclides, following nuclides can be exemplified; 11-carbon (11C), 15-oxygen (150) , 18-fluorine ('8F) , 32-phosphorus (32P) , 59-iron (59Fe) , 67-copper (67Cu) , 67-gallium (67Ga) , 81m-krypton (81mKr) , 81-rubidium (81Rb) , 89-strontium (B9Sr) , 90-yttrium (50Y) , 99m-technetium (99mTc), 111-indium (111In) , 123-iodine (123I) , 125-iodine (125I) , 131-iodine (131I) , 133-xenon (133Xe) , 117m-tin (11'mSn), 153-samarium (153Sm) 186-rhenium ('86Re) , 188-rhenium (188Re) , 201-thallium (201T1) , 212-bismuth (212Bi) , 213-bismuth (213Bi) and 211-astatine (21 'At). As to the diagnostic purpose, 18-fluorine ('6F), 99m-technetium (99mTc), 67-gallium (17Ga) , 111-indium (111In) , 123-iodine (123I) , 131-iodine (131I) and the like are frequently used.
99m-Technetium complex of MAG3 (99mTc-MAG3) is a radiopharmaceutical for in vivo use and is widely used for the purpose of diagnosis of renopathy and uropathy, because it possesses accumulation property to the kidney. It is known that about 90% of 99mTc-MAG3 bind to plasma protein. For this reason, in vitro study was conducted by using 99mTc-MAG3 as the first drug, the serum as the plasma protein, wherein the blood cells and blood coagulation factors are removed, and several pharmaceuticals with the binding affinity for serum proteins as the second drug. As the result, when bucolome, valproic acid, warfarin or the like was added, then displacement of 99mTc-MAG3 occurred either in human serum albumin or in rat serum albumin, thus the free fraction of 59mTc-MAG3 in serum albumin increased. In case of bucolome, the free fraction of 99mTc-MAG3 particularly increased (Table 1). Fig. 5 shows time course of accumulation of 99mTc-MAG3 in the rat kidney after administering 20 mg/kg of Bucolome. Fig. 6 shows the biodistributions in rats at 10 minutes after the administration of 99mTc-MAG3. In this case, 10 minutes before the administration of 99mTc-MAG3, 100 mg/kg of bucolome was administered. These results show that the amount of free 99mTc-MAG3 was increased by bucolome loading, and rapid clearance from the blood and accumulation of 99mTc-MAG3 into the kidney took place.
Regarding 99m-technetium complex of diethyl ester of N,N'-ethylene-L-cystein (99mTc-ECD), which is a radiopharmaceutical used for scintigraphy of regional 5 cerebral blood flow, in the in vitro experiment by using a human serum, the displacement effect was observed by adding Etoposide (cf. Example 4 and Table 8).
For the purpose to prove the displacement effect on organic compounds, in vitro and in vivo 10 experiments were conducted by using N-isopropyl-p-iodoamphetamine (1z3I-IMP) as one example of organic compounds. In im vitro experiments, the displacement effects were observed by adding warfarin or 6-methoxy-2-naphthylacetic acid (6-MNA), both of which have the 15 specificity to HSA, or by adding verapamil which has the binding specificity to AGP (cf. Example 5 and Table 9), thus the displacement effect on organic compounds was observed and proved. Further, in the experiments by using 6-MNA and Verapamil in which those were added separately or added simultaneously, the synergistic effect of the displacement effect was observed, thus it is indicated that the displacement effect can be enhanced by using plural second drugs together (cf.
Example 6 and Table 10).
In in vivo experiments in rats, as compared with the control group (unloaded with verapamil), the higher concentration of free 123I-IMP in blood was observed in the test group (loaded with verapamil).
Reflecting the fact, 10 minutes after the administration, the brain uptake of 123I-IMP in the test group (loaded with verapamil) was about 2 times that in the control group (Example 7). In this ,fin vivo experiments, the test solution containig both of 123I-IMP
and verapamil was prepared in advance (Example 7 (1)) and used it in the experiment. Results of Example 7 indicates that it is possible to regulate the free drug concentration by simultaneous administration of the first and second drugs using their mixture as well as by the separate administration of the first drug and the second drugs and the biodistribution of the first drug could reflect it.
As for an example of the reducing effect of the free drug concentration, decrease in the free fraction (i.e., increase in binding fraction to protein) was observed in in vitro experiment using N-(3-fluoropropyl)-2Q-carbomethoxy-3Q-(4-iodophenyl)-nortropane labeled with radioactive iodine (1-125) (1251_ FP-CIT) together with human serum by adding dansyl-L-asparagine (DNSA) which is specific to the site I on albumin (cf. Example 8 and Table 15).
EXAMPLES
The present invention will be explained in more detail by illustrating the following examples, but the invention will not be restricted only to these examples.
- - - ---------- -Methods for testing the compounds obtained and the reagents used are as follows.
(1) Ultrafiltration: Filtration was conducted by using an equipment of ULTRACENT-10 which treats for up to 1.5 ml (manufactured by Tosoh Corp.).
(2) 99mTcO,-: Prepared by use of a 99Mo/99mTc generator of MEDITECH (manufactured by NIHON
MEDI-PHYSICS CO., LTD.) and used its eluent as in the form of a physiological saline solution.
(3) Reagents: The all reagents used were "Extra-pure reagent grade".
(4) Test animals: The all test animals used were Wister-strain male rats (body weight: 200-250g).
Prior to the test, the animals were breeded under light-dark cyclic condition in every 12 hours for 1 week, and had free access to food and water.
Example 1 Examination of displacement effects of the second druas on 99mTc-MAG3 binding to plasma protein Displacement test of 99mTc-MAG3 binding to serum albumin was conducted as follows by use of human serum or rat serum and site-specific drugs (second drugs) with binding affinity for the binding site I or site II on albumin. Bucolome, valproic acid, warfarin and cefazolin were used as site-specific drugs with binding affinity for the site I, and ibuprofen, sodium octanoate and sodium oleate were used as site-specific drugs with binding affinity for the site II.
First, albumin content in a normal human serum was measured previously, and the concentration of the human serum albumin (HSA) was adjusted to 500 /IM by phosphate buffer (pH=7.4).
Further, a site-specific drug with the binding affinity for the site I or the site II on HSA was added to the above-mentioned serum solution, as in the form of a methanol solution or an aqueous solution. As the sample solution for control group, only methanol or water was added to the above-mentioned serum solution.
Next, a certain amount of 99mTc-MAG3 (about 740 kBq/20 121) was added to each of the sample and a certain amount (20-50 121) of the sample was taken out as the specimen before ultrafiltration. Each 0.9 mL of the samples was put in a ultrafilter and conducted ultrafiltration under the condition of 1500 X g, for 10 minutes. Then, 20-50 11.1 each of the filtrates was taken out as the specimen after ultrafiltration.
Radioactivities (cpm) of the specimens before and after ultrafiltration were measured, and the free fraction (%) of 99mTc-MAG3 was calculated by the following equation:
free fraction of 99mTc-MAG, (%) = [A]/[B]
[A]: Radioactivity (cpm) after ultrafiltration, [B]: Radioactivity (cpm) before ultrafiltration Similarly, albumin content in normal rat serum was previously measured, and the concentration of the rat serum albumin (RSA) was adjusted to 375 UM by phosphate buffer (pH=7.4) so as to conduct the test similar to that of the case of human serum. The results are shown in Table 1, Fig.l and Fig.2.
In the case of human serum, the free fraction (%) of 99mTc-MAG3 in the test samples to which a site-specific drug to site I was added, such as bucolome, valproic acid, warfarin or cefazolin, was significantly increased as compared with the free fraction (10.2%) of 99mTc-MAG3 of the control sample.
On the other hand, in other test samples to which a site-specific drug to site II was added, such as ibuprofen, sodium octoate or sodium oleate, increase in the free fraction was not observed.
Similarly, in test samples of the rat serum to which a site-specific drug to site I was added, increase in the free fraction (%) of 99mTc-MAG3 was observed.
As can be seen from the above results, it is clearly indicated that the free fraction of 99mTc-MAG3 in the blood can be increased by adding a site-specific drug to site I. Although, warfarin, octanoic acid and oleic acid might be considered clinically unsuitable for the purpose of this invention, they were used for the confirmation of the effects of site-specific drugs to the binding site.
+ o\C OP o\C o\o o\o z~ Ln C) Co N
U) H 0 O 00 M N O I I
Pi 41 O M Ol M m U ~' N cf M M
(o r I t 0\0 u=) r I r1 o\C
M N
I N
U U) I o\C oW o\C o\o o\C
U Co [- Co CO
9 - ÃE- If' Ln ~t I I
(o i R+ i p N aD M CD CO
I~' N M (N M N N
U
(1) U) o\C o\C o\C o\o o\C o\o o\o C N r lD M
00 O t` O C l.f) CD w -T
Q' '- M M M IT O
v ' rI ci r-I ,-1 Ol Ol 4-i U
a 1 o\C
U o r-i 4-4 H b Of 4-4 O 4- O
O
o 0 a U) I. \o o\o o\o o\C o\C
U o\C OP
E CD
' (N (3) L r--1 to [~
U (f) b -1 r~ Oo N -i o rn ao a a N
U) a) U
rI
4-4 r4 H -H O I~ Z7 U U 0 =r-1 -r-I
U
U 4J ro N b co I~ r -H
(0 ~4 S a (1) U s~ =r-I 4) U U
Q1 CP -0 a--( r=-1 E -r=1 -ri r-1 4-4 -r-1 Ti U
(C) O 'O 0 (Ti 0 0 r- 0 U 4J O Q, 4-4 (Ti Q, (o -H
S~ s~ U r- 4-4 -P N
0 0 (0 (0 N A U r-I
U U A 3 U =r-1 0 0 Example 2 Bi odi stri buti on of 99mTc-MAG, in rat loaded with bucolome Effect of second drug on biodistribution of 99mTc-MAG3 in rat was examined using the control group and the test group with bucolome loading. 99mTc-MAG3 (740 kBq/100 LLl) was administered to the tail vein of Wister-strain rat. The rats were decapitated at 2, 5, and 15 minutes after administration of 99mTc-MAG3, then the blood and the organs of interest were excised.
10 After measured the weight of these orgams, the radioactivities were determined. After decay correction of the radioactivity, the accumulation ratios (% dose/
organ and % dose/g of the tissue) were determined.
As for the rat of test group loaded with bucolome, 5 minutes before the administration of 99mTc-MAG3, 20 mg/kg of body weight or 100 mg/kg of body weight of bucolome was administered to the tail vein.
The results are shown in Table 2 and Table 3 (control group), Table 4 and Table 5 (test group, loaded with 20 mg/kg of bucolome) and Table 6 (test group, loaded with 100 mg/kg of bucolome).
In the control group and test group with bucolome loading of 20 mg/kg of body weight, wherein the dose and other conditions were the same as mentioned above, except the decapitation time was prescribed at 2, 5 and 10 minutes, administrations and decapitations of rats were conducted so that 3-5 ml of blood per one rat were collected. Serum was separated using a sample tube, after that the free fraction was determined by the procedures as described in Example 1. The time course of the free fraction of 99mTc-MAG3 in vivo are shown in Fig. 4.
From the results shown above, it has become appearant that blood clearance was accelarated in the test group with bucolome loading (Fig. 3), and the free fraction of 99mTc-MAG3 in vivo in test group was remarkably increased (Fig. 4).
In the control group, accumulation of 99mTc-MAG3 in the kidney (% dose/organ) increased from 2 minutes to 5 minutes after the administration, then gradually decreased and disappeared. While, in test group with bucolome loading, accumulation of 99mTc-MAG3 in the kidney rapidly increased to the maximum value just after the administration (in 2 minutes), then decreased and disappeared quickly as compared with that of the control group (Fig. 5).
Biodistribution of 99mTc-MAG3 (% dose/g tissue) in rat 10 minutes after the administration is shown in Fig. 6. As can be seen from Fig. 6, in the test group with bucolome loading, 99mTc-MAG3 was rapidly cleared from the kidney which is the target organ of 99mTc-MAG3, thus radioactivity was quickly cleared as compared with that of the control group. Clearance from the blood and other organs were also rapid.
C) o c v' o 0 o O to l0 0 00 Ln N O 0 O N Cl O 0 r-i +1 +1 +1 +1 +1 +1 +1 +1 H c1 0 CO M 'IT C1 Cl E r-I M N N 0 M N '-1 (d O O -i Ol CO O r-i IzT
0) Ln ~-I r1 O O O O U) O O CO
O r-1 M
4) U) l0 O M C) 0) Co N N
0 U) O U7 V O) N N lqr lz~' a) C) O O O N O O O
4i 0\0 O O O O M O O t7 +1 +1 +1 +1 +1 +1 +1 +1 U a E Ln 'IT 0) r-1 00 0) Ln N
N CO '-i N Cil N N N
O O O O r-I l0 r-i O (N CO
4-4 O O Ol c; O lO
0 N r1 r-i O
0 -A M M Ol m to l0 -4 O
=-i W O -4 O T) v O lt' O O O N 0) 0 r-I 0) 4J rl U) O O O O O O O
+1 +1 +1 +1 +1 +1 +1 +1 a--I r 0) 0) N V lqr ;;r C) U) a--i H lfl N I'D CO (N CO 0) O
r-i O O r-i v -I M r-i U M
Lf) O O O LC) r O O .-I
O
ri i~
c =ri l0 r1 N Cl Cl l0 01 N N r-I Co 0 M "i r-I
N U) O O O M I'D O 1-4 ri J-) O O O O T O O O
r +1 +1 +1 +1 +1 +I +1 +1 H O N l0 l0 N N L() 110 (d I M N 0) CO l0 M M
H r i v- N r-I CO N Q0 N
N
O O O Lf) M O O O
N
U) u) a) U >1 0) U E N f~ H
tP r/-'~i C 0 (d > ZS >~ = ri H aD4 (0 41 = i =r N H4 0 co a co a x x a N ~O r O ~' N O N
U) N O O LU N N r1 if) O O O O O N O O
O O O O O r-1 O O
+1 +I +1 +1 +1 +1 +I +1 U) E O 110 co O O N N (N
U) l0 N I7' 1-4 O O L '-i rl ~f) -4 O O .-i r -I (N O r1 O O O O O 0o c; O
a) U) co CD ['N O 0i m -1 co 0 U) ri O N rI O l0 M O
'CS a) O O O O O N O O
.1J
o\o O O O O O N O O
1 +1 +1 +1 +1 +1 +1 +1 +1 U E N l0 In U-) 110 CO M
co Ol .-I N N r-i 0 O M CD CD O .-i Ln r1 (\J
C C C C C U C C
44 b~
O
O N co N I7' d O 1 l0 41 U) -1 O ri l0 m l0 =ri 4J ri O O O N dl O O
Q O C C C ) * O O
+1 +1 +1 +1 +1 +1 +1 +I
CD Q' O r-1 (n .--I O O
- U) l0 O Ln M (N N 0l [--.H (0 Ln T, 0 O O O O O O
O
m -H
1~ r1 Ol r1 r I d l0 O
U
M M N -I CO rn LU O
M 4--1 r1 O O O O r1 O r1 O O O O O M O O
ri +1 +1 +1 +1 +1 +1 +1 +1 (N .-i M l0 0) Ol CD r1 fly co N M r- N M 'IT N
E N V r1 N r-I Ln O c)' l0 r1 O O C C M O O
'-i U) U) a) U >1 N S-I (0 ~-I a) 4-1 (d 0 a) U E a) S-I t tT 0 r-I r~ 0 > C m r.
~4 r-1 Q.~ (0 41 -.-I = H a) 0 m Cl) a co a x x a Ln M M O N Ln U-) N
O Ln c' Co Ln N O
U) C) O O ri ) O O
a) co +1 +1 +1 +1 +1 +I +1 +1 ri c-i Ln c' to 0) Ln rn U) r N O O N OD l0 .4-) N O O r-i CO LC) O O Ol rd E Ln r-I O O O O Ol O O M
~4 0 N
rI U
Ol M N LI) N Ol N
U) O N M N 0) -1 N C) Q) 0 O O v' (N O O M
J--) : O O CD, c; CO O O lzT
U +1 +1 +I +1 +1 +1 +1 +1 CO O r-i N CO N CO N
(~ i lC) -i r-i r4 M 0) O 0) O O O -i N r-i O r-i N
L~4 -4 O O O O i N O O
o O
F m O r I U) W
= O M Ln [ Ql N r-i "o U) '-i O O M N M r-I M N
a) 00\0 O O O O O al O O N
4 +1 +1 +1 +1 +1 +1 +1 +1 -P tm H CO Ol m O N IT lO N
U ~' M if) U) r-I Ln 01 -1 to ' H C) r-i r-i r-i m -4 l0 O a) (0 O O O M N O O N
'H H 0 (N
'-i N N M M d' cl 0) O N Ln m 11:31 M C) cr U) U O O O M N O O ( r-+1 +I +1 +1 +1 +1 +1 +I
itl rl M Ol Ol 0) K' O N N
H E: O M CO CO O '-i ' C) r-i N N N T (N [`N co (N O O O N O O O O
N
U) U) a) U >1 b 4) U E; 4) 7-i tT ,~
C1 r=-I S' 0 / 'b m r~ =H
4--I Cl) (Ti 4-1 -,H r i N
0 ) a U) a x x a co 110 N N co M .--1 O
U) co O Ln .-i N N N N
a) CD O CD O CD OD O O
O O O O O -I O O
+1 +1 +1 +1 +1 +1 +1 +1 N co OD N co Ol Ln r-i Ln -1 CO M co O CT OD
Ln ~-i O O CD CD CO O O
O O O O O O O
U) -W N
m E O r-I r-I O Ln r r O, ~-1 O V) r ri (N (N Cn lO r i d --i a) O O CD O O OD O O
O
O O O O O M O O
+1 +1 +1 +1 +1 +1 +1 +1 Q rI O l) (N M r CO r O
00 N lO M .--1 Ln LO N
,x r-i c:) O O c-i Ln O .-I
U O
E U) O JJ M Ln r r r O r-i M
a-1 N ' CD -1 r--1 ,--1 lO N r O U) CD CD CD CD O N CD CD
O O O O O O O O
+1 +1 +1 +1 +1 +1 +1 +1 f-I -,-i v' (r) Ln M O O N C
ow r d' OD ~' M 00 Ln r r 0 Ln CD rl O N CD r-i m ~-1 S -I Ln a--1 O O O O O T-1 O O
U) co r co M '-I LO Ol M
O a) (d Ln -i r-i N Ch r C7 1-1 I H 0 CD O (D -I rI M O CD
CLl -i U) (D O O O O O O O O
= +1 +I +1 +1 +f +I +1 +1 Un O C I~zv Ln CU Ol m CU
=ri Ln Ln r-I c1' L(=) w N r QI O . 1 M c I co O U lD
A N i O O O O (4 O O
cU -1 Ei U) co O U >1 a) S i (0 $-1 a) -W
0 ((0 0 a+ 0 > b ~-i -i a (0 4J -H =ri a) 0 m U) QI Cl) a x x a Table 6. Biodistribution of 9 Tc-MAG3 in rats minutes after the administration (Test group with 100 mg/kg bucolome loading: % dose/g tissue) Control group Test group Organs with bucolome loading Blood 0.317 0.073 0.047 0.044 Brain 0.010 0.001 0.001 0.001 Spleen 0.052 0.008 0.009 0.008 Pancreas 0.046 0.000 0.006 0.007 Stomach 0.024 0.024 0.040 0.036 Liver 0.151 0.001 0.033 0.026 Kidney 6.191 0.187 0.651 0.324 Heart 0.101 0.016 0.014 0.010 Lung 0.195 0.030 0.043 0.037 5 Example 3 Examination of displacement effect on 99mTc-MAG., by means of renography in rats By using Wistar-strain rats (body weight:
400g), displacement effect of bucolome on 99mTc-MAG3 was 10 examined by means of renography in rats. Prism 3000 (picker) was used as an apparatus.
A catheter was inserted into the femoral vein of the rat, then 99mTc-MAG3 (11.1 MBq) was injected through the catheter and the control renogram was obtained. The dynamic imaging was conducted 10 seconds/scan for 20 minutes. About 2 hours after, confirming the urination and decrease in background radioactivity, then bucolome was loaded to the same rat.
Bucolome was dissolved in ethanol and adjusted as in the dose of 20 mg/kg, then intravenously injected by using a microinjector taken in 10 minutes. About 5 minutes after finish of the intravenous injection of bucolome, 99mTc-MAG3 was intravenously injected through the catheter and the renogram was taken similarly by 10 seconds/scan for 20 minutes. Fig. 7 shows the renogram (time-radioactivity curves in the kidney) used for functional analysis of the kidney. As can be seen from the Fig. 7, in the control group, the radioactivity curve went up gradually at the initial stage after the administration, and the peak time was 240 seconds. On the other hand, in the test group with bucolome loading, the radioactivity curve rose quickly, and the peak time was 120 seconds which was a half length of that of the control group. Renal function is usually analyzed by determination of the peak time in this renogram and a slope of the straight line in a linear regression. By inhibiting the binding ability of 99mTc-MAG3 to plasma protein, the renogram was obtained as close to an ideal and was apploximated to a simple curve. Thus, the functional analysis of the kidney can be easily carried out, and the time for functional analysis can be shortened by shortening the peak time.
Table 7. Analytical results of renogram of 99mTc-MAG3 in rats Peak time Slope (Second) (Count/second) Rat 1 Control group 240 1.166 Test group (with bucolome loading) 110 2.208 Rat 2 Control group 170 0.941 Test group (with bucolome loading) 120 2.000 Example 4 Examination of displacement effects of the second drugs on 99mTc-EDC binding to plasma protein Displacement experiment of 99mTc-ECD binding to a serum albumin was conducted by procedures similar to 5 those shown in Example 1 using human serum; and bucolome, valproic acid, warfarin and cefazolin with binding specificity to the site I on albumin; ibuprofen and sodium octanoate with binding specificity to the site II on alubumin; and etoposide with binding 10 specificity to HAS on which binding site is not identified. The results are shown in Table 8.
As compared with the free fraction (26.03%) of 99mTc-ECD in human serum shown in control group, the free fraction of 99mTc-ECD in human serum were remarkably 15 increased in test group by etoposide, both at the concentration of 200 9M and 400 4M. Similarly, the free fraction of 99mTc-ECD in human serum were also incresed by bucolome, valproic acid and warfarin, but were not remarkably shown as compared with that of 20 etoposide. On the contrary, the free fraction of 99mTc-ECD in human serum were not clearly increased by ibuprofen and sodium octanoate which have the specificity to the site II on albumine.
Table 8 Displacement of 99mTc-ECD binding to plasma protein Site-specific free fraction of drug 99mTc-ECD ( % ) (second drug) Concentration 200 u M 400 gm Control 26.03%
Bucolome 28.62% 30.25%
Valproic acid 28.36% 30.250 Warfarin 31.00% 31.37%
Cefazolin 25.92% 27.40%
Etoposide 33.26% 37.38%
Ibuprofen 23.09% 24.09%
Octanoic acid 28.22% 29.64%
Example 5 Examination of displacement effects of the second drug on 123I-IMP binding to plasma protein Displacement experiment of 123I-IMP binding to a serum albumin was conducted by procedures similar to those shown in Example 1 using human serum; and as the second drug, bucolome and warfarin with binding specificity to the binding site I on albumin; ibuprofen, sodium octanoate, 6-methoxy-2-naphthylacetic acid (6-MNA) with binding specificity to the binding site II on alubumin; and verapamil which has the specificity to al-acid glycoprotein (AGP). Concentration of the second drug (e.g., bucolome) was 400 4M and added amount of 1231-IMP was about 220 kBq/20 9L. The results are shown in Table 9.
As compared with free fraction (29.29%) of 1231-IMP in human serum shown in control group, the free fraction of 123I-IMP in human serum in test group was remarkably incresed by adding verapamil with binding specificity to AGP. Further, the free fraction of 1231-IMP binding in human serum in test group was also increased by warfarin and 6-MNA mainly bound to albumin.
In view of these facts, it is suggested that 1231-IMP
binds to the binding site on both albumin and AGP, and it is clearly understood that the free fraction of 123I-IMP can be increased by a drug having the specificity to each binding sites of these proteins.
Table 9. Displacement of 1231-IMP binding to human plasma protein (Concentration of the site-specific drug was 400u M) Site-specific drug free of fraction of 123I-IMP (%) (second drug) Control 29.29%
bucolome 30.26%
warfarin 34.69%
ibuprofen 28.43%
octanoic acid 28.74%
6-MNA 32.70%
verapamil 38.34%
Example 6 Examination of displacement effects of the second drugs on 1231-IMP binding to plasma protein; synergistic effect Displacement experiment of 123I-IMP binding to serum albumin was conducted by procedures similar to those shown in Example 5 using human serum and as the second drugs, 6-MNA having the specificity to the binding site II on albumin and verapamil having the specificity to the binding site on AGP. Concentration of the second drugs were 400 AM and the added amount of 123I-IMP was about 220 kBq/20 UL.
The tests were conducted in one group by using 6-MNA or verapamil independently, and in another group by using 6-MNA and verapamil simultaneously to study synergistic effect. In both groups, concentrations of the second drugs were 400 UM. The results are shown in Table 10.
In case of using 6-MNA and verapamil simultaneously, the free fraction of 123I-IMP was over than the sum of the corresponding values obtained by single use of 6-MNA or verapamil, respectively. In view of the above facts, synergistic effect can be expected by using the plural second drugs.
Table 10. Displacement of 123I-IMP binding to human plasma protein: synergistic effect Site-specific drug free fraction of 123I-IMP
(second drug) Control 26.52%
6-MNA 30.00%
verapamil 33.87%
6-MNA + verapamil 39.26%
Example 7 Biodistribution of 1211_IMP in rat with verapamil loading (1) Preparation of 12 3I-IMPverapamil mixed solution 35 Milligrams of verapamil bulk drug powder was dissolved in 2 ml of Vasolan injection (verapamil 5 mg/2 ml, manufactured by Eisai Co., Ltd.), then 34 f LL
of 123I-IMP injection (111 MBq/ml, manufactured by NIHON
MEDI-PHYSICS CO., LTD.) was added thereto and mixed throughly.
(2) Biodistribution of z'I-IMP in rats Control group: 123I-IMP Injection solution (185 kBq/300 /.GL) being diluted with physiological 5 saline was administered via the caudal vein of rats of control group. The rats were decapitated at 2, 5, 10, 30 and 60 minutes after administration. Then the blood was sampled and the organs of interest were excised.
After measured the weight of these specimens, the 10 radioactivities of the blood and organs were measured.
After half-life of the radioactivities were corrected, the accumulation rate (% dose/g of the tissue) was obtained.
Test group: 100 /_GL of 123I-IMPverapamil mixed 15 solution was administered via the caudal vein of rats of the test group (about 10 mg/kg loaded as verapamil), then the rats were treated similarly to those of control group. The results of biodistribution of 123I-IMP are shown in Table 11 (control group), Table 12 (test group 20 with verapamil loading), and Table 13 (comparison of both control and test groups of 10 minutes after the administration).
(3) Examination of displacement effect on 123I-IMP
binding to plasma protein in rat 25 Under the same conditions as mentioned above concerning the constitution of control and testing group, timings of decapitation, and dose of drugs, administrations of the drugs and decapitations of rats were conducted, and 3-5 ml of blood per one rat was sampled. Serum was separated using a sample tube, after that the free fraction of 123I-IMP was determined by the procedures as described in Example 1. The free fraction of 1231-IMP in the blood sample of rat obtained at each decapitation timing are shown in Table 14.
As shown in Table 14, it is clearly indicated that the free fraction of 1231-IMP in the blood sample of rat were increased by the loading with the verapamil.
As shown in Table 11 through Table 13, corresponding to increasing in the free fraction of 123I-IMP in the blood due to the loading with verapamil, the uptake of 1231-IMP into the brain which is the target organ of 1231-IMP was rapidly increased after administration of 123I-IMP=verapamil mixed solution in the test group, thus the brain uptake of 123I-IMP in the test group after the administration was increased about 2 times higher than that of shown in control group. These facts indicate that, even if a mixed drug of the first drug and the second drug is administered (simultaneous administration of the first drug and the second drug), the free fraction of 1231-IMP can be regulated by the second drug, and the biodistribution of the first drug could reflect it.
l0 r-1 Ln co ro N l0 110 O r-I C' ('') I-V lfl (U N r1 O O O M r-i m r-i r-1 O 110 O O O O O O O O O
+I +I +I + + +I +I + +i r-i r-I N O Ln N Ln O to 00 r--I Ln 0, ;:3' IZ3' co 't' co O '-i Ln 0l N N Ln Ln r-1 O r-i r-i I r I r i r I O Ln 00 Ln Ln N to to N l lO
to N :T O N I'D M N (n a) O M Ln N M Ln N O
O O O O O O O O r-I
+ + +I +I +I + + + +
U) Z-+ to to N to LO N Ol 01 4W M d' M Ln 00 0) Ln N O
b N O M O M O r-1 M Ln N
f=4 CU
U) O r1 N r-1 O rH r i O Ln { U) a H
r I 0) N CI' O (U C) r -I l0 H U) r-I 1- r-1 N M 1;3' 0) 1-1 N
a) C) ('7 N O N r-i .-i -1 O
a) 4--i O O O O O C) O O r1 Q .9 + + + + + + + + +I
4-1 l0 to r-1 CO I- r-I M -1 0) O o\o r-i O N O O 1--1 O M N
O r-I O (- O C (- C Q0 N
Cl o O , 1 r i .H O O r-i c; to r1 O
A is Ln Ln Ln Ln co ,-i w o C) ~4 U) O N IZT Ln N l0 Ln N O
4J O a) O (N M O O N O l0 U) ~4 4J
.H 4--I O O O O O O O O O
O O +I +I +I +I +I +1 +I +1 +1 .,.j V H M l0 M 0, C) 0) Ln C) X M N N 0, O 0, ao r-1 O
Ln r-I 7 0) 0) Ln l0 N O O
r i C) r-i H O O O N r-I 0) c--i a) N co M lfl Ln 0, LO M
E-l U) Ln r f Lf) r I l0 O O 0) 00 C) I' M N O r-1 0) N
O O O O O O O O
+1 +1 +1 +1 +1 +1 +1 +1 +1 { CO O (U O N l0 l0 0) M
0) O C) CO C) C) C) I'll N r I co LO co m Ln IZ1 O, N
O r I H O O O (U r-1 r-i U) U) 0.j 1;
a) a) U >1 ~4 a) (d ~4 a) 4.) U) 0 -,-1 U a) a) 1~ N CT
U) 0 (d rl '-i 0 > b (d 1~
=r-1 r-1 ~i (d Pa 4.) -11 -r-I a) H a as a (n Cl) a x x a N -i r-A 0 l0 .~ dl 0) U) O CO 110 N N LO C Cr) r=
a) O N c-i r I ri O ri O O
O O O O O O O O O
+I +I +I +I +I + +I +I +
O O) CO M CO 0) N 1,0 M
r-i 'I' r 0) Ln Cr) v' un Cr O r-I ct ll 1-4 O lO N C' 11 O. r--I r-i c-I r-i r-I r1 O c7' c1 r i l0 0) r I r i N 0) Cr) U) -i co r-I N If) Cr) C) N
O CO CO M lO r= lO N N
U) O O O O O O O O N
U) +I +I + + + + + + +I
E-+ O 0) N l0 N LI) r i 4 O
0) N N CO CO CO M r= 0) O C) LC) CO CO N r 4 N co I:v M
a) O r i r1 O O r-i r~ O M
U) Q
0\0 Cr) O LI) CO Cr) N CO 0) O
O r( 00 ri -4 Cr) r= C) CD
a) C) l0 r-i O N l0 N C
U) r-I O O O O O O O O r I
+ + + + + + + + +I
m u7 ri M r= CO -O r- r-Q, M c1 rI r= co lO I1' IT
O N M lO N N 0) O N ' -I O O O r I r-I lO
a ~ N .--I l0 O CO O r-I O M
U) ri Cr) Cl u7 [^- Cr) 00 CO O
0) O r-i i N O r-I Cr) 110 In L" a) 41 0 O CD- c; O O O O O
a +1 +1 +1 +1 +1 +1 +1 +1 +1 - co ~0 m Cr) ItT O CO O r-0 v N -i LI) l0 l0 to r= l0 r-. -i N 01 lO O ri M N N M
A 04 O ,-i r I O O O r-I N O
ri 0 4- b = rl -W Cr) In In In r-I lO M r-i CO
U) U) CD N I- N r-i l) r-i r-I ' 0 a) a) O ~zv M O r-i r-I Cr) 0) r`
O O O O O O O O r-i +I +1 +1 +1 +1 +1 +I +1 +1 CO C' co N C' I- lzzv 0) 'Z' N Z Cr) CO l0 In Cr) CO N lO Cr) N In N O N N C' I- N
N
O r1 ri O O O r-I M 0) r~
rd U) Ul (d .1.1 () a) U >1 1 0 =.~
U) -i u a) E a) ~4 U) 0 td r, r-i 0 J 10 (a -ri r--4 4-I (d a 4-1 -ri =ri a) i H CQ W a U) En 4 x x a Table 13. Biodistribution of 123I-IMP in rats minutes after the administration (% Dose/g Tissue) Test group with Tissue Control group verapamil loading Blood 0.116 0.011 0.139 0.003 Brain 1.006 0.379 2.145 0.410 Pancreas 1.721 0.217 1.911 0.685 Spleen 1.008 0.074 0.213 0.118 Stomach 0.407 0.230 0.377 0.013 Liver 0.711 0.143 0.688 0.237 Kidney 1.303 0.190 1.766 0.678 Heart 0.631 0.111 1.247 0.209 Lung 6.279 1.026 6.947 1.486 U) a) 1 N
JJ ~' OD
+1 +1 (- to r- co O
O L() o, O co +1 +1 U) .11 0) m -+ N O
(1 f4 O CO
44 (n N M
O V) N c1' rl a) r-I M
0) +1 +1 ~" -H ri to Cl co O
a H
r- co M M
U) 4-I O d O
+I +1 -H
o\o O (N
r- Ln L O
O LO `n U
rd y.4 O
U) N O
a) a) a) 0) +1 +1 w .H Ln C) z N lfl N
LC) Ln a) ro H
4J 'd Q H cd o rH o cra 4J ro U) ~4 o a) a) U H
Example 8 Examination of regulating the free fraction of Experiment was conducted by procedures similar to those shown in Example 5 using human serum and as the second drug, bucolome, phenylbutazone, warfarin and dansyl-L-asparagine (DNSA) with binding specificity to the binding site I on albumin, and ibuprofen, 6-methoxy-2-naphthylacetic acid (6-MNA) with binding specificity to the binding site II on albumin.
Concentration of the second drug (e.g., bucolome and the like) were 400 /_LM and added amount of 1211-FP-CIT
was about 74 kBq/20 LLL. The result are shown in Table 15.
As compared with the free fraction (17.26%) of 1211-FP-CIT in human serum shown in control group, the free fraction of 123I-FP-CIT in test group was remarkably decresed by DNSA. Furthermore, the free fraction of 123I-FP-CIT in test group was also decreased by phenylbutazone and ibuprofen. In view of these facts, it is clearly understood that the free fraction of the first drug can be decreased by the second drug having the binding affinity for the plasma proteins.
Table 15. Free fraction of 123I-FP-CIT in human serum (concentration of the site-specific drug was 400 /iM) Site-specific drug free fraction (%) of 121, -FP-CIT
(second drug) Control 17.26%
bucolome 18.40%
hen lbutazone 14.92%
warfarin 17.88%
DNSA 12.80%
ibu rofe 15.92%
6-MNA 18.10%
- - -------- - -
verapamil 38.34%
Example 6 Examination of displacement effects of the second drugs on 1231-IMP binding to plasma protein; synergistic effect Displacement experiment of 123I-IMP binding to serum albumin was conducted by procedures similar to those shown in Example 5 using human serum and as the second drugs, 6-MNA having the specificity to the binding site II on albumin and verapamil having the specificity to the binding site on AGP. Concentration of the second drugs were 400 AM and the added amount of 123I-IMP was about 220 kBq/20 UL.
The tests were conducted in one group by using 6-MNA or verapamil independently, and in another group by using 6-MNA and verapamil simultaneously to study synergistic effect. In both groups, concentrations of the second drugs were 400 UM. The results are shown in Table 10.
In case of using 6-MNA and verapamil simultaneously, the free fraction of 123I-IMP was over than the sum of the corresponding values obtained by single use of 6-MNA or verapamil, respectively. In view of the above facts, synergistic effect can be expected by using the plural second drugs.
Table 10. Displacement of 123I-IMP binding to human plasma protein: synergistic effect Site-specific drug free fraction of 123I-IMP
(second drug) Control 26.52%
6-MNA 30.00%
verapamil 33.87%
6-MNA + verapamil 39.26%
Example 7 Biodistribution of 1211_IMP in rat with verapamil loading (1) Preparation of 12 3I-IMPverapamil mixed solution 35 Milligrams of verapamil bulk drug powder was dissolved in 2 ml of Vasolan injection (verapamil 5 mg/2 ml, manufactured by Eisai Co., Ltd.), then 34 f LL
of 123I-IMP injection (111 MBq/ml, manufactured by NIHON
MEDI-PHYSICS CO., LTD.) was added thereto and mixed throughly.
(2) Biodistribution of z'I-IMP in rats Control group: 123I-IMP Injection solution (185 kBq/300 /.GL) being diluted with physiological 5 saline was administered via the caudal vein of rats of control group. The rats were decapitated at 2, 5, 10, 30 and 60 minutes after administration. Then the blood was sampled and the organs of interest were excised.
After measured the weight of these specimens, the 10 radioactivities of the blood and organs were measured.
After half-life of the radioactivities were corrected, the accumulation rate (% dose/g of the tissue) was obtained.
Test group: 100 /_GL of 123I-IMPverapamil mixed 15 solution was administered via the caudal vein of rats of the test group (about 10 mg/kg loaded as verapamil), then the rats were treated similarly to those of control group. The results of biodistribution of 123I-IMP are shown in Table 11 (control group), Table 12 (test group 20 with verapamil loading), and Table 13 (comparison of both control and test groups of 10 minutes after the administration).
(3) Examination of displacement effect on 123I-IMP
binding to plasma protein in rat 25 Under the same conditions as mentioned above concerning the constitution of control and testing group, timings of decapitation, and dose of drugs, administrations of the drugs and decapitations of rats were conducted, and 3-5 ml of blood per one rat was sampled. Serum was separated using a sample tube, after that the free fraction of 123I-IMP was determined by the procedures as described in Example 1. The free fraction of 1231-IMP in the blood sample of rat obtained at each decapitation timing are shown in Table 14.
As shown in Table 14, it is clearly indicated that the free fraction of 1231-IMP in the blood sample of rat were increased by the loading with the verapamil.
As shown in Table 11 through Table 13, corresponding to increasing in the free fraction of 123I-IMP in the blood due to the loading with verapamil, the uptake of 1231-IMP into the brain which is the target organ of 1231-IMP was rapidly increased after administration of 123I-IMP=verapamil mixed solution in the test group, thus the brain uptake of 123I-IMP in the test group after the administration was increased about 2 times higher than that of shown in control group. These facts indicate that, even if a mixed drug of the first drug and the second drug is administered (simultaneous administration of the first drug and the second drug), the free fraction of 1231-IMP can be regulated by the second drug, and the biodistribution of the first drug could reflect it.
l0 r-1 Ln co ro N l0 110 O r-I C' ('') I-V lfl (U N r1 O O O M r-i m r-i r-1 O 110 O O O O O O O O O
+I +I +I + + +I +I + +i r-i r-I N O Ln N Ln O to 00 r--I Ln 0, ;:3' IZ3' co 't' co O '-i Ln 0l N N Ln Ln r-1 O r-i r-i I r I r i r I O Ln 00 Ln Ln N to to N l lO
to N :T O N I'D M N (n a) O M Ln N M Ln N O
O O O O O O O O r-I
+ + +I +I +I + + + +
U) Z-+ to to N to LO N Ol 01 4W M d' M Ln 00 0) Ln N O
b N O M O M O r-1 M Ln N
f=4 CU
U) O r1 N r-1 O rH r i O Ln { U) a H
r I 0) N CI' O (U C) r -I l0 H U) r-I 1- r-1 N M 1;3' 0) 1-1 N
a) C) ('7 N O N r-i .-i -1 O
a) 4--i O O O O O C) O O r1 Q .9 + + + + + + + + +I
4-1 l0 to r-1 CO I- r-I M -1 0) O o\o r-i O N O O 1--1 O M N
O r-I O (- O C (- C Q0 N
Cl o O , 1 r i .H O O r-i c; to r1 O
A is Ln Ln Ln Ln co ,-i w o C) ~4 U) O N IZT Ln N l0 Ln N O
4J O a) O (N M O O N O l0 U) ~4 4J
.H 4--I O O O O O O O O O
O O +I +I +I +I +I +1 +I +1 +1 .,.j V H M l0 M 0, C) 0) Ln C) X M N N 0, O 0, ao r-1 O
Ln r-I 7 0) 0) Ln l0 N O O
r i C) r-i H O O O N r-I 0) c--i a) N co M lfl Ln 0, LO M
E-l U) Ln r f Lf) r I l0 O O 0) 00 C) I' M N O r-1 0) N
O O O O O O O O
+1 +1 +1 +1 +1 +1 +1 +1 +1 { CO O (U O N l0 l0 0) M
0) O C) CO C) C) C) I'll N r I co LO co m Ln IZ1 O, N
O r I H O O O (U r-1 r-i U) U) 0.j 1;
a) a) U >1 ~4 a) (d ~4 a) 4.) U) 0 -,-1 U a) a) 1~ N CT
U) 0 (d rl '-i 0 > b (d 1~
=r-1 r-1 ~i (d Pa 4.) -11 -r-I a) H a as a (n Cl) a x x a N -i r-A 0 l0 .~ dl 0) U) O CO 110 N N LO C Cr) r=
a) O N c-i r I ri O ri O O
O O O O O O O O O
+I +I +I +I +I + +I +I +
O O) CO M CO 0) N 1,0 M
r-i 'I' r 0) Ln Cr) v' un Cr O r-I ct ll 1-4 O lO N C' 11 O. r--I r-i c-I r-i r-I r1 O c7' c1 r i l0 0) r I r i N 0) Cr) U) -i co r-I N If) Cr) C) N
O CO CO M lO r= lO N N
U) O O O O O O O O N
U) +I +I + + + + + + +I
E-+ O 0) N l0 N LI) r i 4 O
0) N N CO CO CO M r= 0) O C) LC) CO CO N r 4 N co I:v M
a) O r i r1 O O r-i r~ O M
U) Q
0\0 Cr) O LI) CO Cr) N CO 0) O
O r( 00 ri -4 Cr) r= C) CD
a) C) l0 r-i O N l0 N C
U) r-I O O O O O O O O r I
+ + + + + + + + +I
m u7 ri M r= CO -O r- r-Q, M c1 rI r= co lO I1' IT
O N M lO N N 0) O N ' -I O O O r I r-I lO
a ~ N .--I l0 O CO O r-I O M
U) ri Cr) Cl u7 [^- Cr) 00 CO O
0) O r-i i N O r-I Cr) 110 In L" a) 41 0 O CD- c; O O O O O
a +1 +1 +1 +1 +1 +1 +1 +1 +1 - co ~0 m Cr) ItT O CO O r-0 v N -i LI) l0 l0 to r= l0 r-. -i N 01 lO O ri M N N M
A 04 O ,-i r I O O O r-I N O
ri 0 4- b = rl -W Cr) In In In r-I lO M r-i CO
U) U) CD N I- N r-i l) r-i r-I ' 0 a) a) O ~zv M O r-i r-I Cr) 0) r`
O O O O O O O O r-i +I +1 +1 +1 +1 +1 +I +1 +1 CO C' co N C' I- lzzv 0) 'Z' N Z Cr) CO l0 In Cr) CO N lO Cr) N In N O N N C' I- N
N
O r1 ri O O O r-I M 0) r~
rd U) Ul (d .1.1 () a) U >1 1 0 =.~
U) -i u a) E a) ~4 U) 0 td r, r-i 0 J 10 (a -ri r--4 4-I (d a 4-1 -ri =ri a) i H CQ W a U) En 4 x x a Table 13. Biodistribution of 123I-IMP in rats minutes after the administration (% Dose/g Tissue) Test group with Tissue Control group verapamil loading Blood 0.116 0.011 0.139 0.003 Brain 1.006 0.379 2.145 0.410 Pancreas 1.721 0.217 1.911 0.685 Spleen 1.008 0.074 0.213 0.118 Stomach 0.407 0.230 0.377 0.013 Liver 0.711 0.143 0.688 0.237 Kidney 1.303 0.190 1.766 0.678 Heart 0.631 0.111 1.247 0.209 Lung 6.279 1.026 6.947 1.486 U) a) 1 N
JJ ~' OD
+1 +1 (- to r- co O
O L() o, O co +1 +1 U) .11 0) m -+ N O
(1 f4 O CO
44 (n N M
O V) N c1' rl a) r-I M
0) +1 +1 ~" -H ri to Cl co O
a H
r- co M M
U) 4-I O d O
+I +1 -H
o\o O (N
r- Ln L O
O LO `n U
rd y.4 O
U) N O
a) a) a) 0) +1 +1 w .H Ln C) z N lfl N
LC) Ln a) ro H
4J 'd Q H cd o rH o cra 4J ro U) ~4 o a) a) U H
Example 8 Examination of regulating the free fraction of Experiment was conducted by procedures similar to those shown in Example 5 using human serum and as the second drug, bucolome, phenylbutazone, warfarin and dansyl-L-asparagine (DNSA) with binding specificity to the binding site I on albumin, and ibuprofen, 6-methoxy-2-naphthylacetic acid (6-MNA) with binding specificity to the binding site II on albumin.
Concentration of the second drug (e.g., bucolome and the like) were 400 /_LM and added amount of 1211-FP-CIT
was about 74 kBq/20 LLL. The result are shown in Table 15.
As compared with the free fraction (17.26%) of 1211-FP-CIT in human serum shown in control group, the free fraction of 123I-FP-CIT in test group was remarkably decresed by DNSA. Furthermore, the free fraction of 123I-FP-CIT in test group was also decreased by phenylbutazone and ibuprofen. In view of these facts, it is clearly understood that the free fraction of the first drug can be decreased by the second drug having the binding affinity for the plasma proteins.
Table 15. Free fraction of 123I-FP-CIT in human serum (concentration of the site-specific drug was 400 /iM) Site-specific drug free fraction (%) of 121, -FP-CIT
(second drug) Control 17.26%
bucolome 18.40%
hen lbutazone 14.92%
warfarin 17.88%
DNSA 12.80%
ibu rofe 15.92%
6-MNA 18.10%
- - -------- - -
Claims (18)
1. Use, in the manufacture of a medicament, of:
a first drug having a binding affinity for a plasma protein;
wherein the first drug is a radiotherapeutic drug having a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150), 18-fluorine, (18F), 32-phosphorus (32P), 59-iron (59Fe) 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (81Rb) 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99m Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201Tl), 212-bismuth (212Bi), 213-bismuth (213Bi) or 21.1-astatine (211At) ; and wherein the binding group of the first drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and a second drug having a binding affinity for the plasma protein;
wherein the second drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the second drug binds to the plasma protein, thereby decreasing the binding of the first drug to the plasma protein.
a first drug having a binding affinity for a plasma protein;
wherein the first drug is a radiotherapeutic drug having a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150), 18-fluorine, (18F), 32-phosphorus (32P), 59-iron (59Fe) 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (81Rb) 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99m Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201Tl), 212-bismuth (212Bi), 213-bismuth (213Bi) or 21.1-astatine (211At) ; and wherein the binding group of the first drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and a second drug having a binding affinity for the plasma protein;
wherein the second drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the second drug binds to the plasma protein, thereby decreasing the binding of the first drug to the plasma protein.
2. Use, in the manufacture of a medicament, of:
a first drug having a binding affinity for a plasma protein;
wherein the first drug is a radiotherapeutic drug having a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150), 18-fluorine, (18F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (81Rb) , 89-strontium (89)Sr), 90-yttrium (90Y), 99m-technetium (99Tc), 111-indium (111In), 123-iodine (1231), 125-iodine (125I), 131-iodine (1311), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201Tl), 212-bismuth (212Bi), 213-bismuth (213Bi) or 211-astatine (211At) ; and wherein the binding group of the first drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and a second drug having a binding affinity for the plasma protein;
wherein the second drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the second drug binds to the plasma protein, thereby increasing the binding of the first drug to the plasma protein.
a first drug having a binding affinity for a plasma protein;
wherein the first drug is a radiotherapeutic drug having a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150), 18-fluorine, (18F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (81Rb) , 89-strontium (89)Sr), 90-yttrium (90Y), 99m-technetium (99Tc), 111-indium (111In), 123-iodine (1231), 125-iodine (125I), 131-iodine (1311), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201Tl), 212-bismuth (212Bi), 213-bismuth (213Bi) or 211-astatine (211At) ; and wherein the binding group of the first drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and a second drug having a binding affinity for the plasma protein;
wherein the second drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the second drug binds to the plasma protein, thereby increasing the binding of the first drug to the plasma protein.
3. Use, in the manufacture of a medicament, of:
a drug having a binding affinity for the plasma protein;
wherein the drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
wherein the drug is formulated for administration either before or after a radiotherapeutic drug having a binding affinity for a plasma protein;
wherein the radiotherapeutic drug has a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150), 18-fluorine, (16F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (81Rb) 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99m Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201T1), 212-bismuth (212Bi), 213-bismuth (213Bi) or 211-astatine (211At); and wherein the binding group of the radiotherapeutic drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and whereby the drug binds to the plasma protein, thereby decreasing the binding of the radiotherapeutic drug to the plasma protein.
a drug having a binding affinity for the plasma protein;
wherein the drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
wherein the drug is formulated for administration either before or after a radiotherapeutic drug having a binding affinity for a plasma protein;
wherein the radiotherapeutic drug has a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150), 18-fluorine, (16F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (81Rb) 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99m Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201T1), 212-bismuth (212Bi), 213-bismuth (213Bi) or 211-astatine (211At); and wherein the binding group of the radiotherapeutic drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and whereby the drug binds to the plasma protein, thereby decreasing the binding of the radiotherapeutic drug to the plasma protein.
4. Use, in the manufacture of a medicament, of:
a drug having a binding affinity for the plasma protein;
wherein the drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
wherein the drug is formulated for administration either before or after a radiotherapeutic drug having a binding affinity for a plasma protein;
wherein the radiotherapeutic drug has a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150), 18-fluorine, (18F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (81Rb), 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201Tl), 212-bismuth (2:12Bi), 213-bismuth (213Bi) or 211-astatine (211At); and wherein the binding group of the radiotherapeutic drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and whereby the drug binds to the plasma protein, thereby increasing the binding of the radiotherapeutic drug to the plasma protein.
a drug having a binding affinity for the plasma protein;
wherein the drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
wherein the drug is formulated for administration either before or after a radiotherapeutic drug having a binding affinity for a plasma protein;
wherein the radiotherapeutic drug has a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150), 18-fluorine, (18F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (81Rb), 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201Tl), 212-bismuth (2:12Bi), 213-bismuth (213Bi) or 211-astatine (211At); and wherein the binding group of the radiotherapeutic drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and whereby the drug binds to the plasma protein, thereby increasing the binding of the radiotherapeutic drug to the plasma protein.
5. The use according to claim 1 or 2, wherein the second drug has binding affinity to the same binding sites on the plasma protein, to which the first drug has binding affinity.
6. The use according to claim 3 or 4, wherein the drug has binding affinity to the same binding sites on the plasma protein, to which the radiotherapeutic drug has binding affinity.
7. The use according to claim 1 or 3, wherein the binding group of the first drug as defined in claim 1, or the radiotherapeutic drug as defined in claim 3, is mercaptoacetylglycylglycylglycine (MAG3), and the second drug as defined in claim 1, or the drug as defined in claim 3, is bucolome, valproic acid or cefazolin; or wherein the binding group of the first drug as defined in claim 1, or the radiotherapeutic drug as defined in claim 3, is ethylenecysteine dimer (ECD), and the second drug as defined in claim 1, or the drug as defined in claim 3, is bucolome, valproic acid or etoposide; or wherein the binding group of the first drug as defined in claim 1, or the radiotherapeutic drug as defined in claim 3, is N-isopropylamphetamine (IMP), and the second drug as defined in claim 1, or the drug as defined in claim 3, is verapamil or 6-methoxy-2-naphtyl acetic acid.
8. The use according to claim 2 or 4, wherein the binding group of the first drug as defined in claim 2, or of the radiotherapeutic drug as defined in claim 4, is tropane, and the second drug as defined in claim 2, or the drug as defined in claim 4, is dansyl-L-asparagine (DNSA), phenylbutazone or ibuprofen.
9. A pharmaceutical composition for decreasing the binding of a first drug to plasma protein, which comprises:
a first drug having a binding affinity for plasma protein;
wherein the first drug is a radiotherapeutic drug having a binding group being labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150), 18-fluorine, (18F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (B1Rb), 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99m Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re) 201-thallium (201Tl) , 212-bismuth (212Bi), 213-bismuth (213Bi) or 211-astatine (211At); and wherein the binding group of the first drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and at least one second drug having a binding affinity for the plasma protein;
wherein the at least second drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the at least one second drug binds to the plasma protein, thereby decreasing the binding of the first drug to the plasma protein.
a first drug having a binding affinity for plasma protein;
wherein the first drug is a radiotherapeutic drug having a binding group being labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (150), 18-fluorine, (18F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (B1Rb), 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99m Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re) 201-thallium (201Tl) , 212-bismuth (212Bi), 213-bismuth (213Bi) or 211-astatine (211At); and wherein the binding group of the first drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and at least one second drug having a binding affinity for the plasma protein;
wherein the at least second drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the at least one second drug binds to the plasma protein, thereby decreasing the binding of the first drug to the plasma protein.
10. A pharmaceutical composition for increasing the binding of a first drug to the plasma protein, which comprises:
a first drug having a binding affinity for plasma protein;
wherein the first drug is a radiotherapeutic drug having a binding group being labeled with a radioactive nuclide:
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (15C)), 18-fluorine, (18F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (81Rb), 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99m Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I ) , 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm) , 186-rhenium (186Re), 188-rhenium (188Re) 201-thallium (201T1) , 212-bismuth (212Bi), 213-bismuth (213Bi) or 211-astatine (211At) ; and wherein the binding group of the first drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and at least one second drug having a binding affinity for the plasma protein;
wherein the at least second drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the at least one second drug binds to the plasma protein, thereby increasing the binding of the first drug to the plasma protein.
a first drug having a binding affinity for plasma protein;
wherein the first drug is a radiotherapeutic drug having a binding group being labeled with a radioactive nuclide:
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (15C)), 18-fluorine, (18F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (81Rb), 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99m Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I ) , 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm) , 186-rhenium (186Re), 188-rhenium (188Re) 201-thallium (201T1) , 212-bismuth (212Bi), 213-bismuth (213Bi) or 211-astatine (211At) ; and wherein the binding group of the first drug is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and at least one second drug having a binding affinity for the plasma protein;
wherein the at least second drug is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the at least one second drug binds to the plasma protein, thereby increasing the binding of the first drug to the plasma protein.
11. The pharmaceutical composition according to claim 9 or 10, wherein the at least one second drug has binding affinity to the same binding sites on the plasma protein, to which the first drug has binding affinity.
12. The pharmaceutical composition according to claim 9, wherein the binding group of the first drug is mercaptoacetylglycylglycylglycine (MAG3), and the second drug is bucolome, valproic acid or cefazolin; or wherein the binding group of the first drug is ethylenecysteine dimer (ECD), and the second drug is bucolome, valproic acid or etoposide; or wherein the binding group of the first drug is N-isopropylamphetamine (IMP), and the second drug is verapamil or 6-methoxy-2-naphtyl acetic acid.
13. The pharmaceutical composition according to claim 10, wherein the binding group of the first drug is tropane, and the second drug is dansyl-L-asparagine (DNSA), phenylbutazone or ibuprofen.
14. A kit for non-medical diagnostic imaging, the kit comprising:
a first container containing a first substance having a binding affinity for plasma protein;
wherein the first substance is a radiodiagnostic substance having a binding group labeled with a radioactive nuclide:
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (15O), 18-fluorine, (18F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krvpton (81m Kr), 81-rubidium (81Rb), 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99m Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201Tl), 212-bismuth (212Bi), 213-bismuth (213Bi) or 211-astatine (211At); and wherein the binding group of the first substance is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and a second container containing a second substance having a binding affinity for the plasma protein;
wherein the second substance is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
together with written instructions for their use for non-medical diagnostic imaging;
whereby the second substance binds to the plasma protein, thereby decreasing or increasing the binding of the first substance to the plasma protein.
a first container containing a first substance having a binding affinity for plasma protein;
wherein the first substance is a radiodiagnostic substance having a binding group labeled with a radioactive nuclide:
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (15O), 18-fluorine, (18F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krvpton (81m Kr), 81-rubidium (81Rb), 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99m Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201Tl), 212-bismuth (212Bi), 213-bismuth (213Bi) or 211-astatine (211At); and wherein the binding group of the first substance is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and a second container containing a second substance having a binding affinity for the plasma protein;
wherein the second substance is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
together with written instructions for their use for non-medical diagnostic imaging;
whereby the second substance binds to the plasma protein, thereby decreasing or increasing the binding of the first substance to the plasma protein.
15. Use, in the manufacture of a diagnostic composition, of:
a first substance having a binding affinity for a plasma protein;
wherein the first substance is a radiodiagnostic having a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (15O), 18-fluorine, (18F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (81Rb) 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99m Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201Tl), 212-bismuth (212Bi), 213-bismuth (213Bi) or 211-astatine (211At); and wherein the binding group of the first substance is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and a second substance having a binding affinity for the plasma protein;
wherein the second substance is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the second substance binds to the plasma protein, thereby decreasing the binding of the first substance to the plasma protein.
a first substance having a binding affinity for a plasma protein;
wherein the first substance is a radiodiagnostic having a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (15O), 18-fluorine, (18F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (81Rb) 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99m Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201Tl), 212-bismuth (212Bi), 213-bismuth (213Bi) or 211-astatine (211At); and wherein the binding group of the first substance is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and a second substance having a binding affinity for the plasma protein;
wherein the second substance is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the second substance binds to the plasma protein, thereby decreasing the binding of the first substance to the plasma protein.
16. Use, in the manufacture of a diagnostic composition, of:
a first substance having a binding affinity for a plasma protein;
wherein the first substance is a radiodiagnostic drug having a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (15O), 18-fluorine, (18F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (81Rb), 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99m Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201Tl), 212-bismuth (212Bi), 213-bismuth (213Bi) or 211-astatine (211At); and wherein the binding group of the first substance is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and a second substance having a binding affinity for the plasma protein;
wherein the second substance is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the second substance binds to the plasma protein, thereby increasing the binding of the first substance to the plasma protein.
a first substance having a binding affinity for a plasma protein;
wherein the first substance is a radiodiagnostic drug having a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (15O), 18-fluorine, (18F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (81Rb), 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99m Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201Tl), 212-bismuth (212Bi), 213-bismuth (213Bi) or 211-astatine (211At); and wherein the binding group of the first substance is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and a second substance having a binding affinity for the plasma protein;
wherein the second substance is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
whereby the second substance binds to the plasma protein, thereby increasing the binding of the first substance to the plasma protein.
17. Use, in the manufacture of a diagnostic agent, of:
a substance having a binding affinity for the plasma protein;
wherein the substance is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
wherein the substance is formulated for administration either before or after a radiodiagnostic substance with binding affinity for a plasma protein;
wherein the radiodiagnostic substance has a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (15O), 18-fluorine, (18F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (81Rb) 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99m Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201Tl), 212-bismuth (212Bi), 213-bismuth (213Bi) or 211-astatine (211At); and wherein the binding group of the radiodiagnostic substance is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and whereby the substance binds to the plasma protein, thereby decreasing the binding of the radiodiagnostic substance to the plasma protein.
a substance having a binding affinity for the plasma protein;
wherein the substance is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
wherein the substance is formulated for administration either before or after a radiodiagnostic substance with binding affinity for a plasma protein;
wherein the radiodiagnostic substance has a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (15O), 18-fluorine, (18F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (81Rb) 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99m Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201Tl), 212-bismuth (212Bi), 213-bismuth (213Bi) or 211-astatine (211At); and wherein the binding group of the radiodiagnostic substance is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine]
(tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof; and whereby the substance binds to the plasma protein, thereby decreasing the binding of the radiodiagnostic substance to the plasma protein.
18. Use, in the manufacture of a diagnostic agent, of:
a substance having a binding affinity for the plasma protein;
wherein the substance is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
wherein the substance is formulated for administration either before or after a radiodiagnostic substance with binding affinity for a plasma protein;
wherein the radiodiagnostic substance has a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (15O), 18-fluorine, (18F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (81Rb), 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99m Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201T1), 212-bismuth (212Bi), 213-bismuth (213Bi) or 211-astatine (211At); and wherein the binding group of the radiodiagnostic substance is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof;and whereby the substance binds to the plasma protein, thereby increasing the binding of the radiodiagnostic substance to the plasma protein.
a substance having a binding affinity for the plasma protein;
wherein the substance is bucolome, cefazolin, etoposide, phenylbutazone, acetyl salicylic acid, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil or disopyramide, or any combination thereof;
wherein the substance is formulated for administration either before or after a radiodiagnostic substance with binding affinity for a plasma protein;
wherein the radiodiagnostic substance has a binding group labeled with a radioactive nuclide;
wherein the radioactive nuclide is 11-carbon (11C), 15-oxygen (15O), 18-fluorine, (18F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (81Rb), 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99m Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201T1), 212-bismuth (212Bi), 213-bismuth (213Bi) or 211-astatine (211At); and wherein the binding group of the radiodiagnostic substance is a bisaminothiol, a monoaminomonoamidobisthiol, a bisamidobisthiol, a mercaptoacetylglycylglycylglycine, a hexamethylpropyleneamineoxime, an ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin), a 2,3-dimercaptosuccinic acid, an ethylenecysteine dimer derivative, a methoxyisobutylisonitrile derivative, a polyamine derivative, a pyridoxylydene aminate derivative, a methylene diphosphonate, a hydroxymethylene diphosphonate derivative, a .beta.-methyl-.omega.-phenylpentadecanoic acid, a N-isopropylamphetamine, a hippuric acid, a benzylguanidine, a tropane derivative, or any combination thereof;and whereby the substance binds to the plasma protein, thereby increasing the binding of the radiodiagnostic substance to the plasma protein.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11/173514 | 1999-06-21 | ||
| JP17351499 | 1999-06-21 | ||
| PCT/JP2000/004039 WO2000078352A1 (en) | 1999-06-21 | 2000-06-21 | Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2376159A1 CA2376159A1 (en) | 2000-12-28 |
| CA2376159C true CA2376159C (en) | 2010-09-14 |
Family
ID=15961945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2376159A Expired - Fee Related CA2376159C (en) | 1999-06-21 | 2000-06-21 | Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7029653B1 (en) |
| EP (1) | EP1197227B9 (en) |
| JP (1) | JP4343473B2 (en) |
| AT (1) | ATE372785T1 (en) |
| CA (1) | CA2376159C (en) |
| DE (2) | DE60036382T4 (en) |
| ES (1) | ES2290042T3 (en) |
| WO (1) | WO2000078352A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2290042T3 (en) * | 1999-06-21 | 2008-02-16 | Nihon Medi-Physics Co., Ltd. | METHOD OF ADMINISTRATION OF PHARMACOS WITH AFFINITY OF UNION TO PLASMATIC PROTEIN AND PREPARATION TO BE USED IN THE METHOD. |
| AU2003262025A1 (en) * | 2002-09-12 | 2004-04-30 | Nihon Medi-Physics Co., Ltd. | Preparation for controlling binging of drug to plasma protein |
| DE60335133D1 (en) * | 2002-10-31 | 2011-01-05 | Nihon Mediphysics Co Ltd | IN VITRO METHOD FOR CLINICAL DIAGNOSIS. |
| GB0427392D0 (en) * | 2004-12-15 | 2005-01-19 | Amersham Plc | Stabilised 99mTc compositions |
| US9321095B2 (en) | 2010-06-30 | 2016-04-26 | General Electric Company | Apparatuses and methods for cutting porous substrates |
| US20160251261A1 (en) * | 2014-03-13 | 2016-09-01 | Stevanato Group International A.S. | Method of Handling a Liquid Drug Formation |
| CN117030905B (en) * | 2023-10-09 | 2024-01-05 | 成都华西海圻医药科技有限公司 | LC-MS/MS analysis method for rapidly quantifying butanedione concentration in blood plasma |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4520112A (en) * | 1983-03-09 | 1985-05-28 | The Johns Hopkins University | Assay method for organic calcium antagonist drugs and a kit for such an assay |
| US4642284A (en) * | 1983-06-13 | 1987-02-10 | Scripps Clinic And Research Foundation | Method and system for detection of complement pathway activation |
| US4976950A (en) | 1988-12-19 | 1990-12-11 | The Dow Chemical Company | Bone marrow suppressing agents |
| US5792444A (en) | 1989-05-09 | 1998-08-11 | The General Hospital Corporation | Labeled chemotactic peptides to image focal sites of infection or inflammation |
| US6022541A (en) * | 1991-10-18 | 2000-02-08 | Beth Israel Deaconess Medical Center | Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel |
| ATE314843T1 (en) * | 1996-03-12 | 2006-02-15 | Pg Txl Co Lp | WATER SOLUBLE PACLITAXEL PRODRUGS |
| DE19648629A1 (en) * | 1996-11-12 | 1998-05-14 | Meisegeier Bernhard Dr | Immunoassays for antibodies or antigens |
| ES2290042T3 (en) * | 1999-06-21 | 2008-02-16 | Nihon Medi-Physics Co., Ltd. | METHOD OF ADMINISTRATION OF PHARMACOS WITH AFFINITY OF UNION TO PLASMATIC PROTEIN AND PREPARATION TO BE USED IN THE METHOD. |
-
2000
- 2000-06-21 ES ES00940773T patent/ES2290042T3/en not_active Expired - Lifetime
- 2000-06-21 CA CA2376159A patent/CA2376159C/en not_active Expired - Fee Related
- 2000-06-21 EP EP00940773A patent/EP1197227B9/en not_active Expired - Lifetime
- 2000-06-21 DE DE60036382T patent/DE60036382T4/en not_active Expired - Lifetime
- 2000-06-21 DE DE60036382A patent/DE60036382D1/en not_active Expired - Lifetime
- 2000-06-21 WO PCT/JP2000/004039 patent/WO2000078352A1/en active IP Right Grant
- 2000-06-21 JP JP2001504414A patent/JP4343473B2/en not_active Expired - Fee Related
- 2000-06-21 US US10/018,745 patent/US7029653B1/en not_active Expired - Fee Related
- 2000-06-21 AT AT00940773T patent/ATE372785T1/en not_active IP Right Cessation
-
2006
- 2006-02-14 US US11/353,152 patent/US20060140857A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7029653B1 (en) | 2006-04-18 |
| US20060140857A1 (en) | 2006-06-29 |
| WO2000078352A1 (en) | 2000-12-28 |
| ES2290042T3 (en) | 2008-02-16 |
| JP4343473B2 (en) | 2009-10-14 |
| EP1197227A4 (en) | 2002-12-04 |
| DE60036382T4 (en) | 2008-09-25 |
| EP1197227B1 (en) | 2007-09-12 |
| ATE372785T1 (en) | 2007-09-15 |
| CA2376159A1 (en) | 2000-12-28 |
| DE60036382D1 (en) | 2007-10-25 |
| DE60036382T2 (en) | 2008-06-12 |
| EP1197227A1 (en) | 2002-04-17 |
| EP1197227B9 (en) | 2008-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2530112B2 (en) | Kit containing radiolabeled technetium chelate for measuring renal function | |
| Verbruggen et al. | Technetium-99m-L, L-ethylenedicysteine: a renal imaging agent. I. Labeling and evaluation in animals | |
| Chervu et al. | Radiopharmaceuticals for hepatobiliary imaging | |
| Stillebroer et al. | ImmunoPET imaging of renal cell carcinoma with 124I-and 89Zr-labeled anti-CAIX monoclonal antibody cG250 in mice | |
| US20060140857A1 (en) | Method of the administration of drugs with binding affinity for plasma protein and preparation to be used in the method | |
| JP2008534617A (en) | Poly (peptides) as chelating agents: production methods and uses | |
| Iozzo et al. | In vivo imaging of insulin receptors by PET: preclinical evaluation of iodine-125 and iodine-124 labelled human insulin | |
| Mikołajczak et al. | Radiopharmaceuticals in cardiology | |
| JP5404405B2 (en) | Weakly basic 2-nitroimidazole for noninvasive detection of tissue hypoxia | |
| Komal et al. | Localization Mechanisms of Radiopharmaceuticals | |
| Fritzberg | Current status of renal radiopharmaceuticals | |
| KR20120120990A (en) | Composition for treating liver cancer in humans based on rhenium-188 and method for preparing such a composition | |
| Dewanjee | Mechanism of localization of radiotracers in myocardium in health and disease | |
| Vallabhajosula et al. | Pathophysiology and mechanisms of radiopharmaceutical localization | |
| Verbruggen et al. | Renal radiopharmaceuticals | |
| Essam et al. | Radiolabelling and biological assessment of 99mTc-Mebeverine as a possible tracer for solid tumor diagnosis | |
| Taillefer et al. | Kinetics of conventional and new cardiac radiotracers | |
| Reske | The Metabolism of Radioiodinated Free Fatty Acids in the Heart. Physiological Basis and Cardiac Biokinetics | |
| JPWO2004024188A1 (en) | Formulations for controlling plasma protein binding of drugs | |
| IL303930A (en) | Radiolabelled alpha-v beta-3 and/or alpha-v beta-5 integrins antagonist for use as theragnostic agent | |
| Türker et al. | Radiopharmacology and pharmacokinetic evaluation of some radiopharmaceuticals | |
| Kopka et al. | 18F‐Labeled PET‐Tracers for Cardiological Imaging | |
| Leung | Abbreviated name:[123 I] ITIC,[123 I] ITIC (OH) Synonym: Agent category: Compound | |
| Chopra | Abbreviated name:[68 Ga] 6 Synonym: Agent Category: Compound | |
| Chopra | Abbreviated name:[186 Re] MAMA-BP Synonym: Agent Category: Compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20150622 |